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Advances in lung cancer treatment among older adults require a risk-benefit analysis for 
health professionals, patients, and family members to assess increased survival and 
health-related quality of life (HRQL). The purpose of this study was to assess the effect 
of lung cancer treatment with surgery or tumor ablation on HRQL domains. A lung 
cancer quality of life model guided the study. The research design was a quantitative 
ancillary study in which 70 participants were recruited from those who had already 
consented to undergo a randomized clinical trial of lung cancer treatment. Data consisted 
of repeated administrations (baseline, 1- and 3-months) of the lung cancer symptom 
scale. Participants indicated their physical function, symptomatic distress, and overall 
quality of life experience on an analogue response card. Although randomization in a 
clinical trial ensures equal groups at baseline, self-selection and loss to follow-up in this 
comparative survey led to significant differences between the 2 treatment groups in age 
(p = .049) and average symptomatic distress (p = .007). Statistical analyses were 
performed using generalized estimating equations assuming a negative binomial 
distribution. There were no significant effects from treatment with surgery or tumor 
ablation on HRQL (physical symptoms, symptomatic distress, and overall quality of life 
experience) at 1-month (p = .7794, p = .6395, p = .9318) and 3-months (p = .2616, p = 
.1345, p = .5217) based on Holm-Bonferroni correction (p = .016). The findings indicate 
that among older adults with lung cancer there is no advantage in selecting surgery or 
tumor ablation in terms of effect on HRQL. The study may contribute to positive social 
change by providing lung cancer treatment-specific risk-benefit information affecting 
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Chapter 1: Introduction to the Study 
Introduction 
In this study, I examined issues surrounding the demographic imperative or the 
aging of the population and the corresponding pressure on the United States public health 
systems. These changes include rising life expectancy, aging of work force, ongoing 
migration, and increasing diversity (U.S. Census Bureau, 2015). An increase in life 
expectancy, however, is driving age-related lung cancer incidence. The implication is that 
older adults receiving cancer treatment face worsening health-related quality of life 
(HRQL; Damm, Roeske, and Jacob, 2013). I conceptualized this study based on the aging 
process, cancer incidence among older adults, variety of newer treatments amenable to 
improved survival, and assessment of HRQL physical functioning specifically on older 
adults with lung cancer. In particular, I assessed physical HRQL domain on older adult 
patients (65 years and older) newly diagnosed with lung cancer and undergoing one of 
two treatment modalities: surgery or tumor ablation.Throughout this chapter, I describe 
the background issues in detail, purpose, nature of study, theoretical framework, 
significance, definitions, assumptions, and limitations.  
Background of the Study 
The leading cause of death in the United States was cardiovascular disease from 
1950 to 2010 however, cancer is now by far the leading cause of cancer death among 
both men and women (American Cancer Society [ACS], 2017; National Cancer Institute 
[NCI], 2017). The incidence of most types of cancers is age-dependent and the number of 
older adults 65 years and above is projected to reach 88.5 million by the year 2050 (U.S. 




and disease prevention and control. The U.S. Census Bureau projects that 1 out of 8 
Americans will reach the age of 65 by 2030 (U.S. Census Bureau, 2010; DHHS, 2010).  
The ACS is the national organization that publishes estimates of all cancer 
statistics using projections from past years. The Centers for Disease Control and 
Prevention (CDC) reports actual data from cancer registries but the data are not for the 
most recent years. According to the ACS (2017), the lifetime probability or risk of 
developing lung cancer is 1 in 14 for men and 1 in 17 for women (SEER 2012-2014 
statistics, Howlader et al., 2017). The ACS estimates that out of 234,030 patients newly 
diagnosed with lung cancer, 65.8% (154,050) will die in 2017, which is the highest 
number of deaths among all cancers (ACS, 2017). There are also gender differences in 
case-fatality; men are 2.3 times more likely die from lung cancer (78.8%) compared to 
women (33.6%) (ACS, 2017; CDC, 2016).  
Lung cancer is predominantly a disease of older adults where incidence increases 
with age (NCI, 2017). Men at age 65 have a 50 times greater risk of developing lung 
cancer than men age 25 and three to four times greater risk than men age 45 to 64 (ACS, 
2016). While two-thirds of people diagnosed with lung cancer are 65 years of age or 
older, less than two percent of all cases are among those younger than 45 (ACS, 2016). 
The latest age-adjusted cancer statistics are for years 2010-2014 based on the 
Surveillance, Epidemiology, and End Results (SEER) statistics (Howlader et al., 2017). 
During this period the median age at diagnosis of cancer of the lung and bronchus was 70 
years of age (Howlader et al., 2017).  
The incidence rates of lung and bronchus cancer between 2010 and 2014 were 




women (NCI, 2017). Mortality rates indicate that close to half of those diagnosed with 
lung and bronchus cancer (44.7/100,000) die, where men (55.9/100,000) are more likely 
to die than women (36.3/100,000).  
Lung cancer is classified into four stages (Stages I, II, III, and IV) ranging from 
mild to severe. Only a small portion of cases are diagnosed early at stage I (13.4%) or II 
(2.8%), whereas most of the cases are either diagnosed at stage III (25.0%) or stage IV 
(37.3%) and on over a fifth (21.5%) of cases staging is unknown (Damm et al. 2013; 
Gloeckler, Ries & Eisner, n.d., NCI SEER Survival Monograph, p. 75). Stage IV lung 
cancer is an advanced form of the disease treated with chemotherapy or radiotherapy 
alone or in combination with another therapy. Therefore, due to the nature of the 
advanced stage of disease as well as the type of treatment involved, I limited this study to 
Stages I, II, and III, which were all treated by tumor ablation, or surgery. 
The combination of lung cancer, other comorbidities among older adults (such as 
chronic obstructive pulmonary disease and emphysema), and treatment side effects often 
result in devastating physiological and psychological threats to an older adult patient 
(Wilders, 2006). Furthermore, older adult lung cancer patients usually present specific 
characteristics such as pain, weakness, shortness of breath, hemoptysis, and cough 
(Damm et al., 2013). These lung cancer-related characteristics make the choice of correct 
treatment more difficult because older patients are often undertreated and significantly 
underrepresented in cancer trials (Braun et al. 2011; Di Maio and Perrone, 2003; Pasetto 
et al. 2007). Treatment strategy for lung cancer is strongly dependent on the stage of the 




Treatment therapies for lung cancer include surgery, chemotherapy, radiation 
therapy, embolization, drug therapy (Hoffman, Brintall, von Eye, & Jones et al. 2014), as 
well as minimally invasive therapy such as image-guided tumor ablation (cryoablation, 
radiofrequency ablation or microwave ablation). The treatment approach for lung cancer 
is more aggressive at certain stages of the disease; however, selection of a specific 
treatment is based on the stage of disease and patient’s ability to tolerate aggressive 
interventions (Pasetto et al., 2007). Assessment of toxicity of lung cancer treatment and 
comorbidity has become a focal issue in cancer research because of concerns about the 
high number of older adults suffering from cancer in general (Pasetto et al. 2007). In 
addition to assessment of HRQL among older adults receiving treatment through clinical 
trials, the impact of comorbidity needs adequate exploration among older adults with 
lung cancer (Hoffman et al., 2014; Pasetto et al. 2007; Wao et al. 2013). 
Despite advances in medical research technology and vast lung cancer clinical 
trials, there is little progress in survival from lung cancer among older adults during the 
last decade of their life (Howlader et al., 2017). For example, the overall 5-year relative 
survival for lung cancer patients between 2003 and 2009 was 16.6% (NCI, 2012) and 
increased slightly to 18.1% from 2007-2013 (Howlader et al., 2017). Based on the latest 
SEER data (2007-2014) women have the greatest gains (21.3%) in survival compared to 
men (15.2%).  
Therefore, assessment of the effect of treatment on HRQL has become more 
relevant due to aging of the population living with lung cancer, and significant 
improvement in healthcare as well as medical technology (Bircan et al., 2003). This 




of using HRQL in modern day oncology studies (Balduyck, Hendriks, Lauwers & Van 
Schill, 2007; Bircan et al., 2003; Hoffman et al., 2014; Lyons, Bennett, Nail, & Fromme 
et al., 2014). In the past, older adults over age 65 were considered too frail to undergo 
cancer treatment or the relative survival was inadequate benefit to outweigh the risk of 
treatment. This type of decision-making resulted in limited information on treatment 
effectiveness among those 65 and older (Hsu, Chen, Shih, Ho, Yang et al. 2012). 
Several instruments to measure HRQL in lung cancer were developed for cancer 
clinical trials to assess survival (Anant et al., 2005; Moinpour et al. 2012; Moller and 
Sartipy, 2012; Montazeri et al., 1998). According to Balduyck et al. (2007), HRQL 
assessments obtained through self-administered questionnaires are gaining recognition in 
oncology research and becoming an important part of evaluation criteria in clinical 
decision-making. HRQL encompasses aspects of overall HRQL that affect health—either 
physical or mental (CDC, 2011). HRQL assessments are feasible, useful, and beneficial 
in cancer studies. These measures provide comprehensive assessment of the patient’s 
condition in terms of how the disease is affecting HRQL. 
Assessment of Health-Related Quality of Life Dimensions 
HRQL instruments measure five basic human functioning domains: physical, 
social, and role functioning, mental health, and general health perceptions (Balduyck et 
al, 2007; Cella, et al., 1995; Wilson & Cleary, 1995). These areas of functioning include 
important symptoms such as physical domain (vitality or energy/fatigue, pain, shortness 
of breath, cough, hemoptysis, and lack of appetite, (Damm et al., 2013; Davis, 2012) and 




The importance of HRQL dimensions as the major physical symptoms associated 
with lung cancer treatment are recognized by several researchers (Anant et al., 2005; 
Balduyck et al, 2007; Cella, et al., 1995; Wilson & Cleary, 1995). These authors stated 
that while a patient may suffer distress initially during the duration of the lung cancer it 
may not impact his or her daily activities, but over an extended period, pain and other 
treatment-related stressors such as shortness of breath, poor appetite, and fatigue may 
dominate the patient’s life and thereby cause significant impairment (Anant et al., 200; 
Balduyck et al, 2007; Cella, et al., 1995; Wilson & Cleary, 19955). Some common 
symptoms that influence a lung cancer patient’s HRQL are anxiety, depression, pain, 
fatigue, dyspnea (shortness of breath), and cough (Salvo et al. 2009).  
 There are over 50 HRQL scaled instruments used in lung cancer clinical trials. 
The most widely used are the Functional Assessment of Cancer Therapy (FACT, L 
version), European Organization for Research and Treatment of Cancer (EORTC, both 
versions), and Lung Cancer Symptom Scale (LCSS) (Anant et al., 2005; Damm et al., 
2013; Davis, 2012; Hoffmann et al., 2014; Lemonnier, Guillemin, Arveux, & Clement-
Duchene et al., 2014; Wintner et al. 2013). The functional domain tested, and the 
abbreviation of the scale is shown in Table 1. The physical domain was assessed in the 
six scales used most often. The SF-36 scale was used to assess all five domains, including 
physical, social, role, mental health, general health, while the EORTC assessed all 
domains except mental health, and the FACT assessed all domains except role, and 
mental health (Anant et al., 2005; Moinpour et al. 2012; Moller and Sartipy, 2012; 





HRQL Functional Domains Tested by Scale 
Domain LCSS EORTC FACT SF 36 KPS VAS 
Physical X X X X X X 
Social  X X X   
Role  X  X   
Mental 
Health 
   X   
General 
Health 
 X X X   
Source: Anant et al., 2005; Montazeri et al., 1998; Darke, Donaldson, Cespedes, Johnson 
et al., 2012; Hoffmann et al., 2014; Moinpour et al. 2012; Moller and Sartipy, 2012. 
LCSS—Lung Cancer Symptom Scale, FACT—Functional Assessment of Cancer 
Therapy, EORTC—European Organization for Research and Treatment of Cancer, SF—
Short Form, KPS—Karnofsky Performance Scale, VAS—Visual Analog Scale. 
 
Health-Related Quality of Life by Lung Cancer Treatment Type 
Although the impact of lung cancer treatment on HRQL was assessed through the 
use of different scales and functioning domains, such as physical, role, social, and 
emotional functioning, significant differences among the treatment modalities were not 
documented by researchers using the instruments (see Table 1). Claassens et al. (2011) 
conducted a literature review to determine which type of scales were used more often to 
measure HRQL. They reported that 57% of the authors used EORTC for chemotherapy, 
surgery, radiation therapy, and drug therapy while 13% used LCSS for drug therapy, 
surgery, and radiotherapy. Some studies used the FACT (Cella et al., 1994) while very 
few used the other scales under chemotherapy, drug therapy, surgery, and radiation 
therapy. My review of the studies using the scales in Table 1, indicated that tumor 
ablation has been understudied using scales except for one study that used the Karnofsky 




al., 2005). Table 2 presents the frequency and type of HRQL scale used to assess lung 
cancer treatment. Although in Table 1 the evidence indicates that physical domain was 
assessed using all the scales, examination of the data by treatment modality reveals that 
assessment of tumor ablation on HRQL has received minimal attention. In this study, I 
sought to fill this gap by assessing physical functioning between tumor ablation and 





Assessment of Lung Cancer Treatment by HRQL Scale 
 LCSS EORTC FACT SF36 KPS VAS 
Tumor Ablation 
  Physical 
  Cognitive 
  Mental 
 





+ +++ +  +  
Surgery       
  Chemotherapy + +++ + +   
  Embolization  ++ ++ +  + 
  Drug Therapy ++ +++ ++   + 
       
+++: most clinical trials used the particular type of scale; ++: moderate use of the scale; 
+: few used the scale. LCSS—Lung Cancer Symptom Scale, FACT—Functional 
Assessment of Cancer Therapy, EORTC—European Organization for Research and 
Treatment of Cancer, SF—Short Form, KPS—Karnofsky Performance Scale, VAS—




Lung cancer is the cancer that results in the highest rate of death for both men and 
women, and lung cancer cases make up nearly a quarter of all cancer deaths in the United 
States (NCI, 2012). According to the ACS (2014), the lifetime probability or risk of 
developing lung and bronchus cancer in the United States (2007-2009 statistics) is 1 in 13 
in men and 1 in 16 women. Men age 65 have a 50 times greater risk of developing lung 
cancer than men age 25 and three to four times greater risk than men age 45 to 64 (ACS, 
2014). The U.S. Census Bureau estimates that by the year 2030, one out of eight 
Americans will reach age 65 (US Census Bureau, 2010; DHHS, 2010). 
Lung cancer is age related and leads to higher mortality among older adults as 




times more likely to develop lung cancer in 2 decades compared to men age 30 and older 
women 25 times more likely than younger women are (SEER, 2014). Older adult lung 
cancer patients have complex medical histories as well as a myriad of comorbidities. 
Unique characteristics such as physiological changes in organ function and 
pharmacokinetics add to the risk compared to benefit assessment and are often untreated 
or not given the best treatment (Di Maio & Perrone, 2003). The combination of lung 
cancer comorbidity (such as chronic obstructive pulmonary disease and emphysema), and 
treatment side effects, often results in devastating physiological and psychological threats 
for older adults (Wilders, 2006). Some common symptoms that influence a lung cancer 
patient’s quality of life are anxiety, depression, pain, fatigue, dyspnea (shortness of 
breath), and cough (Salvo et al., 2009; Wintner et al., 2013). Anxiety and depression 
significantly correlate with impaired HRQL (Frick et al., 2007).  
There is a paucity of literature in studies of HRQL among older adults diagnosed 
with cancer, especially lung cancer. The evidence on the ability of key instruments 
(EORTC, KPS, FACT, and LCSS) to predict the effect of treatment on HRQL among 
older adults with lung cancer is mostly conclusive. However, many researchers advocate 
for further studies as there is much to learn about HRQL’s role in cancer clinical trials, 
cancer research in general, utility in treatment planning, and appropriate therapeutic goals 
(Anant et al., 2005; Moinpour et al., 2012; Moller and Sartipy, 2012; Montazeri et al., 
1998). Most of the HRQL literature on lung cancer physical domain is limited to scaled 
assessments on surgery treatment; however, assessment of HRQL on tumor ablation has 
received minimal attention. There are physiological and psychological problems in older 




model for this study that focuses on physical functioning, functioning well-being 
(assessment of well-being is well beyond the scope of this study), symptomatic distress, 
and overall quality of life for lung cancer experience. Therefore, I sought to fill the effect 
of tumor ablation and surgery treatment on HRQL gap by assessing physical functioning, 
symptomatic distress, and overall quality of life experience among older adults with lung 
cancer undergoing tumor ablation and surgery. 
Purpose of the Study 
The purpose of this study was to assess the impact of two lung cancer treatment 
modalities on HRQL physical functioning, symptomatic distress among older adults, and 
the overall quality of life experience among older adults. Lung cancer treatment improves 
both survival and quality of life, yet treatment is underutilized among older adults. 
Insufficient evidence is available as to the extent that different treatments improve HRQL 
and survival. The reasons for underutilization include the unique alterations in physiology 
that place older adults at greater risk of toxicity, comorbid conditions which can further 
reduce tolerance, and underrepresentation of older adults in clinical trials (Anant et al., 
2005; Balduyck et al, 2007; Di Maio & Perrone, 2003; Quoix, 2011). Although new lung 
cancer treatments are available, pessimism delays assessment of the effect of new 
treatment on older adults functioning and survival (Anant et al. 2005; Zimmermann et al. 
2011). Both health care providers and patients need this information to use as evidence 
for decision-making regarding treatment and clinical trial participation.  
Measurement of HRQL can be feasible, worthwhile, and beneficial in cancer 
studies of older adults. My study examined differences in HRQL among older adult lung 




and participation in a randomized clinical trial (Tse et al, 2005; Balduyck et al, 2007). 
Assessment of the effect of lung cancer treatment, such as surgery and tumor ablation, on 
HRQL yielded reliable information to some extent (Balduyck et al, 2007; Anant et al., 
2005; Cella et al, 1995); however, lung cancer is not adequately assessed in terms of 
HRQL among older adults. Some researchers suggest the impact of HRQL domains on 
lung cancer treatment for the older adult and the need for additional studies and further 
evidence on the subject (Larsson, Ljung, and Johansson, 2012; Moller and Sartipy, 2012).  
Nature of the Study 
I selected a quantitative comparative survey of HRQL on older adults newly 
diagnosed with lung cancer undergoing treatment with tumor ablation or surgery. The 
study approach involved an add-on ancillary study to an ongoing randomized clinical 
trial. I recruited participants from the cancer center of a hospital in the Northeastern part 
of the United States. I selected two lung cancer treatment modalities for this study which 
were surgery and an image-guided ablation (tumor ablation). I selected these two because 
surgery remains the most common treatment for lung cancer while tumor ablation is a 
new modality and literature on it is scanty (Anant et al., 2005; Balduyck et al, 2007; Cella 
et al, 1995; Osoba, 2011; Simon and Dupuy, 2005). Chemotherapy and radiotherapy, 
although major therapies used in lung cancer treatment were excluded in this study 
because they are usually used to treat more advanced lung cancer diagnoses such as stage 
IV. The inclusion criteria for the study included patients diagnosed with lung cancer 
stages I through III treated with surgery or tumor ablation; age 65 years and older; male 




To test the effect of lung cancer treatment on physical pain HRQL domains, I 
proposed three research questions and three hypotheses. The dependent variables are the 
six major symptoms associated with lung malignancies, symptomatic distress, and overall 
quality of life for the lung cancer experience. Operational measures for these variables as 
well as detailed statistical plans are discussed in Chapter 3. Specific survey questions are 
listed in Appendices B & F.  
Research Questions and Hypotheses 
Research Question 1: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H01): There are no significant differences in LCSS total scores 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Alternative Hypothesis (Ha1): There are significant differences in LCSS total 
scores between the two lung cancer therapies (surgery or tumor ablation) measured at1-
month and at 3-months period. 
Research Question 2: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 




Null Hypothesis (H02): There are no significant differences in average symptom 
burden index scores between the two lung cancer therapies (surgery or tumor ablation) 
measured at 1-month and at 3-months period. 
Alternative Hypothesis (Ha2): There are significant differences in average 
symptom burden index scores between the two lung cancer therapies (surgery or tumor 
ablation) measured at 1-month and at 3-months period. 
Research Question 3: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H03): There are no significant differences in quality of life 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Alternative Hypothesis (Ha3): There are significant differences in quality of life 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Theoretical Base 
The lung cancer quality of life model developed, by Hollen et al. (1995), titled 
"Quality of Life Dimensions for the Lung Cancer Experience" provided the foundation 
on HRQL (Haywood, Garratt, & Fitzpatrick, 2005; Hollen et al., 1995). The model 
represents the physical dimension as the basic factor that affects an individual’s 
functioning as well as overall perception of quality of life related to lung cancer (Hollen 




dimensions are different concepts; function is related to factors such as activities of daily 
living (walking, eating) and at the same time to activities related to cognitive and social 
functioning.  
The focus of this study is on the physical domains since it is the primary way 
treatment affects older adults compared to young patients who are affected in terms of 
function (activities of daily living and social life), symptomatic distress of the patient as 
well as the overall quality of life experience (Damm et al. 2013; Davis, 2012; Hirsh, 
2014). In addition, the other domains not measured in the study increase participants' 
burden, as they duplicate clinical notes that the cancer center already collects during 
regular doctor's visits (ADLs) and they are not available for research purposes. Overall 
quality of life experience is the outcome and represents the resulting effects of the disease 
on the physical and functional dimensions, and therefore is conceptualized separately. 
This theoretical model for quality of life may explain outcomes of subjective factors 
(pain, cough, fatigue, etc.) assessed in lung cancer therapies throughout the treatment 
(Hollen et al. 1995). 
A set of related concepts and the linkages between them are described in the 
framework; the model is displayed in a diagram (Figure 1). This model allows 
visualization of a specific problem offering better understanding to the concepts and their 
interrelationships. This quality of life profile is based on the model developed for clinical 
and research use on the lung cancer population (Hollen et al. 1995). The model is 
consistent with World Health Organization’s (WHO’s) definition of health, which states 
health is “a state of complete physical, mental, and social well-being, and not merely the 




Constitution, 1946). These concepts and the associated diagram are described further in 
Chapter 2.   
Definitions of Terms 
 The following terms are defined for this study. 
Appetite: a desire or relish for food (www.nlm.nih.gov). 
Cough: Coughing is a reflex that keeps throat and airways clear or forces air from 
the lungs with short sharp noises often when sick. Although it can be annoying, coughing 
helps body heal or protect itself. Coughs can be either acute or chronic (US National 
Library of Medicine, 2014). 
Fatigue: Fatigue can refer to a subjective symptom of malaise and aversion to 
activity or to objectively impaired performance. It has both physical and mental aspects. 
It can be used as a complaint of weariness from bodily or mental exertion, exhaustion, 
and/or toil (Sharpe, M. & Wilks, D., 2002).  
Health-related Quality of Life (HRQL): this construct encompasses those aspects 
of overall quality of life that can be clearly shown to affect health—either physical or 
mental (CDC, 2011). HRQL was measured in this study by a composite score on the 
Lung Cancer Symptom Scale (LCSS; Hollen et al. 1995). 
Hemoptysis: may be defined as coughing up blood that has volume of about 100 
mL in 24 h; causes abnormal gas exchange/airway obstruction; causes hemodynamic 
instability; expectoration of blood from some part of the respiratory tract (Ibrahim, W. 
H., 2008). 
Pain: usually a localized physical suffering associated with bodily disorder, 




experience associated with actual or potential tissue damage or described in terms of such 
damage (International Association for the Study of Pain [IASP], 2012). 
Shortness of Breath: a feeling of difficult or labored breathing that is out of 
proportion to the patient's level of physical activity. It is a symptom of a variety of 
different diseases or disorders and may be either acute or chronic (Frey, 2002). 
Symptomatic Distress: a condition found to be associated with diagnoses in lung 
cancer (Hollen et al. 1995). 
Surgery: an operative procedure for correction of deformities or a process that is 
used to treat lung cancer (ACS, 2015). Participants were placed into this option by 
physician referral.  
Tumor ablation: a process whereby a needle applicator is placed into solid tumors 
using imaging guidance. This treatment option comprises of three major techniques 
(Simon and Dupuy, 2005). Applicators can deliver electric current (Radiofrequency 
ablation), electromagnetic energy (microwave ablation) or intense cold (cryoablation). 
All these ablative techniques destroy tumor in situ. Radiofrequency ablation uses an 
alternating electrical current operating in the frequency of radio waves (460-480 kHz) 
emitted from the tip of an electrode or needle placed directly into targeted tissues within 
the human body. The heat generated is used to destroy the tissues within the body. 
Microwave ablation is an electromagnetic method for inducing tumor destruction using 
devices with frequency of 900 MHz or greater. Cryoablation is a process whereby a local 
application of liquid nitrogen is used as an adjuvant to resection in treating tumors 





There were three assumptions I made in developing this study. The first one is 
that the disease sequelae and treatment side effects of lung cancer are devastating and 
lasting longer than 3months. Second, that participants would answer the questionnaires 
openly and honestly because they were assured their responses would be kept 
confidential and anonymous. Third, that the selected instrument (LCSS) would accurately 
assess and differentiate HRQL measures since they were found to be valid and reliable 
tools and have been confirmed in international standards/studies (Hollen et al. 1995). 
Limitations 
There were two limitations that I identified in this study, including 
generalizability and bias from refusal to participate, loss to follow-up, and mortality. The 
use of a small, sample from one hospital and geographic area may limit the 
generalizability of these findings. However, due to the lack of research on HRQL in the 
older adult participant, placing a higher burden on these participants was a concern, and 
additional studies can be designed later. The devastation of the diagnosis of lung cancer, 
the negative effects of the disease progression, and the treatment side effects may result 
in patients’ reluctance to participate in the study and may cause sample bias and sample 
mortality. Participants will be encouraged but not coerced to participate in the study. 
Delimitations 
There were two delimitations that I made in designing this study, including 
selecting only two lung cancer treatments to compare, and excluding combination 
therapies. This study is limited to examination of differences in older adults’ HRQL from 




chemotherapy and radiotherapy are used as advanced or stage IV therapies (Damm et al., 
2013; Wao et al., 2013). The incidence of lung cancer is rare in young adults. The 
treatment modalities selected for this study are used to treat patients that can be followed-
up regularly and who are expected to recover. There will be no studies of combination 
therapies. To avoid confounders, only stand-alone therapies were considered to capture 
changes in specific treatment. Because this study considered less advanced stages such as 
stages I, II, and III, combination therapies were not included as these are used with 
advanced staged IV lung cancer. The clinical design was not my decision but that of the 
core randomized clinical trial conducting the initial recruitment and enrollment of 
patients. However, a single treatment isolates the symptoms due to one treatment. 
Significance of the Study 
The significance of this study stems from the fact that lung cancer ranks number 
one in incidence of cancer (Damm et al., 2013, SEER, 2014) among both males and 
females, young and old. There is also scarcity of research in lung cancer on older adults 
in terms of HRQL. Prior to this study, the effect of surgery and tumor ablation treatments 
on HRQL were not evaluated substantially. As reviewed in the literature, HRQL is the 
most important predictor of survival for older adult lung cancer patients (Cella et al., 
1995; Damm et al., 2013; Davis, 2012; Hoffmann et al., 2014; Hollen et al., 1995; 
Wintner et al., 2013). The results of this study could be used to determine which cancer 
treatment option is more likely to be tolerated in older adults. Implications from the 
findings of this study may offer decision-making information suitable to older patients in 
clinical settings. This study may add to existing information on quality of life domains. 




advantages and disadvantages of each treatment to HRQL. Furthermore, having 
knowledge of potential changes in HRQL over the course of treatment may add evidence-
based information when selecting medical options. Medical practitioners, nurses, public 
health professionals, clinical social workers, chaplains and other professionals providing 
therapy and counseling to lung cancer patients can do a risk-benefit analysis in their 
decision-making. Evidence-based information may allow providers to understand the 
patients’ perspective and their preferences in HRQL. Taking HRQL into consideration 
may help to provide humane treatment that will meet the potential needs of older adult 
lung cancer patients. 
Summary and Transition 
Lung cancer incidence is higher in older adults compared to other age groups. 
Lung cancer is often not diagnosed until late in progress when case-fatality increases. 
Because of the aggressive process of late stage cancer, the frailty of older adults, and the 
significant impact on physiological and psychological effect that lung cancer treatment 
has on older adults, assessment of HRQL physical functioning, symptomatic distress, and 
lung cancer experience is of major importance. Although the need for humane, effective 
treatment exists, a review of the literature indicated there is a paucity of research on the 
impact various treatment options have on HRQL domains in older adults. The 
effectiveness of newer lung cancer treatment modalities on HRQL has not been 
thoroughly assessment. The purpose of this study was to compare three aspects of HRQL 
among older adult lung cancer patients undergoing treatment with surgery and tumor 
ablation. The physical domain includes individual pain, appetite, shortness of breath, 




life experience. This chapter is followed by a review of the relevant body of literature on 




Chapter 2: Literature Review 
Overview 
The purpose of this study was to assess the effect of lung cancer treatment 
modality on HRQL among older adults. Lung cancer affects all age groups, but mainly 
diagnosed in older adults at a rate of two out of three individuals diagnosed at 65 years 
and older (ACS, 2013). Fewer than three percent of all lung cancers occur among those 
under the age of 45 years (ACS, 2013). The average age at diagnosis is approximately 70 
years (ACS, 2013). Lung cancer consists of two types: small-cell lung cancer (SCLC) 
and non-small-cell (NSCLC). NSCLC constitutes about 80-85% of all lung cancers, 
while SCLC accounts for the remaining 15-20% (Gridelli, Langer, Maione, Rossi, & 
Schild, 2007). More than 50% of cases of advanced NSCLC were diagnosed among 
patients who were older than 65, and about 30-40% of incident cases were diagnosed 
among those older than 70 (SEER, 2016; Gridelli et al., 2005).  
Although the older adult population makes up the fastest-growing segment in the 
United States (U.S. Census Bureau, 2012; 2014), older lung cancer patients are often 
excluded from participating in clinical trials (Gridelli et al., 2005; 2007). Older adult 
patients have traditionally been excluded based on age when enrolling in clinical trials 
involving lung cancer, especially stage III cancer (Gridelli et al., 2005; 2007). However, 
due to technological advances, standard treatment offered, and evidence from clinical 
trials, stage III older adult lung cancer patients are now enrolled without prejudice if they 
can tolerate the treatment offered and do not have significant limitations in functional 




In this chapter, I describe the literature search strategy. I also describe the core 
issues related to the conceptualization of the study, such as the theoretical model, 
pathophysiology of lung cancer, relevant literature on HRQL, lung cancer, and the effects 
of changes in HRQL on lung cancer treatment.  
Literature Search Strategy 
I used the following databases for my literature review: Ovid Online database 
(Health and Psychosocial Instruments), Lifespan Online library (Rhode Island and 
Miriam Hospitals), and Lifespan Library located on campus of a private hospital in 
Northeastern part of the United States. I also used the Walden University library, the 
United States Oncology Review, the Brown University library, and topic-related 
textbooks to search for the most relevant published articles related to this study. The 
search included articles published between 1992 and 2016. Literature published 5-10 
years ago was included because the initial search for the proposal did not yield much 
literature passed 2005. Literature on quality of life for lung cancer patients resurfaced 
since 2014. Older published articles were included because they provided key relevant 
background information about the study topic. The following key words were used as the 
root of all inquiries: health-related quality of life assessment, health-related quality of life 
assessment and lung cancer treatment, lung cancer and health-related quality of life 
measurements, lung cancer and the elderly, and lung cancer treatment modalities and the 
elderly. With these terms, other search words were used to narrow the search: health-
related quality of life as related to tumor ablation and surgery, health-related quality of 




cancer patients, and different methods of cancer treatment, were used to narrow the 
search. 
In the remaining content of the literature review I highlighted seminal research 
capturing the effects of HRQL assessments on lung cancer treatment for older adults. The 
goal was to provide a better understanding of the physiological effects of quality of life 
domains among older adult lung cancer patients. The literature review is organized into 
six sections. The first section consists of the presentation of the conceptual model that I 
used to guide this study. The second section includes the pathophysiology of stages I, II, 
and, III lung cancer. The third section consists of a review of the two different therapies 
under consideration for this study. The fourth section consists of a review on aging 
process as it pertains to lung cancer in older adults. The fifth section consists of a review 
of the ethics of quality of life, while the sixth section includes a discussion of the quality 
of life tools used to guide this study as reviewed in the literature. 
Theoretical Model 
The theoretical model I used to guide this study was the quality of life dimensions 
for the lung cancer experience developed by Hollen et al. (1995). The model is composed 
of three quality of life dimensions: a physical dimension, a functional dimension, and 
overall quality of life (Figure 1). The model conceptualizes a physical dimension as the 
basic dimension that influences functioning as well as overall experience of quality of life 
among those with lung cancer. The developers of the model conceptualized the 
dimension of function as distinct from the physical dimension where physical dimension 
is related to daily activities (walking, eating), and function reflects cognitive and social 




linked to activities such as walking, eating, resting, and is separate from those activities 
that reflect cognitive and social functioning. During the initial stages of lung cancer, it 
may not be evident that the disease is affecting cognitive and social functioning (Hollen 
et al., 1995). Overall quality of life represents a separate dimension and serves as the 
measure of the outcome variable or the effect of lung cancer on the physical and 
functional dimensions. 
The study assessed physical dimensions, symptomatic distress, and overall quality 
of life for the lung cancer experience (Figure 1, pg. 28). The functional dimension, which 
measures functional activities such as walking, eating, resting or ADLs, is not captured in 
the cancer treatment experience until much longer than 3 months of progression and thus 
beyond the scope of this study (Lemonier et al, 2014). In addition, according to the 
principal investigator at the cancer center study site, this dimension is ascertained during 
the clinical process and is not available to link with research data. Attempts to collect this 
type of data represent an unnecessary participant burden, or duplicate clinical notes that 
the cancer center might have already collected during doctor's regular visits and these are 
not available for research purposes. However, symptomatic distress and overall quality of 
life experience among those with lung cancer was explored. There are preconditions, 
which may mediate experience with lung cancer and activity status (ADLs); however, 
these aspects are not as important in evaluating treatment interventions after initial 
diagnosis (Lima et al., 2011). Preexisting factors may have a direct negative effect on 
functional status and quality of life (Lima et al., 2011). According to Hoffman et al. 
(2014) preexisting factors such as unmanaged fatigue may become determining factors in 




The six major physical dimension symptoms (loss of appetite, cough, pain, 
shortness of breath, hemoptysis, and fatigue) of lung cancer are considered common and 
relevant symptoms of lung cancer by oncologists and lung cancer researchers (Damm et 
al., 2013; Davis, 2012; Hirsh, 2014). Alleviation of predominant physical manifestations 
of illness and other symptomatic distress and activity status may impact lung cancer 
treatment more than other dimensions, such as overall quality of life (Hollen et al., 1995; 
Hollen et al., 2006). To properly assess the subjective nature of psychological 
dimensions, the predominant six major symptoms should be assessed separately from 
other forms of symptomatic distress. However, in the conceptual model diagram (Figure 
1) symptomatic distress falls under the physical dimension. Symptomatic distress refers 
to the way the individual perceives the severity of the symptom and occurs in conjunction 
with the major physical symptoms related to quality of life. Symptomatic distress was 
measured as one of the dependent variables. Activity status represents the functional 
dimension and includes social dimension to depict the association with the major physical 
symptoms. Global quality of life includes every dimension that was not detailed 
according to the model but could be linked to lung cancer (Figure 1; Hollen et al., 1995). 
The diagram in Figure 1 was derived from the LCSS where I depict how the study 
was guided by this model. The figure highlights the two concepts (physical dimension 
and quality of life for those who experienced lung cancer) that are operationalized in this 
study to ascertain the HRQL following lung cancer treatment. HRQL physical domains 
which include shortness of breath, pain, fatigue, appetite, cough, hemoptysis, together 
with symptomatic distress (global symptomatic distress from lung cancer) make up the 




overall quality of life for lung cancer experience captures global quality of life, which 
embodies other types of dimensions including cognitive, psychological, social, spiritual, 



























Figure 1. Quality of Life Dimensions for the Lung Cancer Experience 
Source: Quality of Life during Clinical Trials: Conceptual Model for the Lung Cancer 
Symptom Scale. Supportive Care Cancer, 2, 213-222 (Hollen et al., 1995; Appendix D) 
with permission. The concepts highlighted indicate the constructs operationalized in the 
study. 
 
The authors used the model as the basis for their study in measuring quality of life 
in patients with pleural mesothelioma to determine psychometric properties of the Lung 
Cancer Symptom Scale (LCSS)-mesothelioma—LCSS-meso (Hollen et al., 2006; Hollen 
et al., 2004). A modified version from the original LCSS 9-item patient reported scale 
and 6-item observer-reported scale of LCSS were used in two clinical trials. Improved 
scores were found in participants who scored better in terms of performance and had 
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I presented discussion of literature on assessment of smoking and lung cancer 
quality of life due to the limited applied literature using the LCSS by Hollen et al. (1995, 
2004, 2006). The literature on assessment of smoking and lung cancer quality of life adds 
supporting evidence of the model’s ability to assess quality of life. Garces et al. (2004) 
used the LCSS based on the conceptual model by Hollen et al. (1995) to assess the 
relationship between quality of life and cigarette smoking after a diagnosis of lung 
cancer. The researchers recruited the sample between 1999 and 2002 and included 1028 
respondents with lung cancer that were surveyed at the beginning and follow-up post-
treatment for surgery, radiation, and chemotherapy. During diagnosis of lung cancer, 
there was a gradient of quality of life scores across smoking status where those who 
never smoked had the lowest scores (better quality of life), former scores had intermittent 
scores, and persistent smokers had higher LCSS scores (worse quality of life) (Garces et 
al., 2004; Sloan, Zhao, Novotny, Wampfler, Garces et al. 2012). 
LCSS scores were contrasted with various groups of smokers using univariate 
independent group testing and multivariate linear models (Garces et al., 2004). The 
researchers of the study examined quality of life differences among groups of smokers, 
adjusting for gender, age, time of assessment, and stage at diagnosis (Garces et al., 2004). 
There was a clinically significant 10-point difference between groups as being clinically 
significant (Garces et al., 2004; Sloan et al. 2012). The adjusted average total LCSS 
scores for those who never smoked and persistent smokers were 17.6 and 28.7 (Garces et 
al., 2004). The authors found out of the seven individual LCSS quality of life components 
consisting of fatigue, appetite, shortness of breath, cough, lung cancer symptoms, illness 




those who never smoked compared to those who were persistent smokers (Garces et al., 
2004). There were no clinically significant differences for pain or hemoptysis. In 
addition, former smokers had intermediate LCSS scores (Garces et al., 2004). The 
authors therefore concluded that the relationship between smoking status and quality of 
life were supported by their correlational study and that their findings suggested that 
continued cigarette smoking after diagnosis of lung cancer negatively impacted quality of 
life. There was a gradient of quality of life scores across smoking status where those who 
never smoked had the lowest scores (better quality of life), former scores had intermittent 
scores, and persistent smokers had higher LCSS scores (worse quality of life) (Garces et 
al., 2004; Sloan et al. 2012). 
Pathophysiology of Lung Cancer 
Lung cancer forms in the lungs within the cells, which line the air passages 
(American Cancer Society [ACS], 2013). Lung cancer is a very aggressive disease and if 
not detected early enough can have a very poor outcome (ACS, 2013). According to the 
ACS recent estimates, in 2013 there were 228,190 new cases that included small cell and 
non-small cell lung cancer diagnoses in the United States and 159,480 deaths from lung 
cancer (ACS, 2013). Between both genders, lung cancer is the leading cause of cancer 
death (ACS, 2013). The American Cancer Society (2013) stated that lung cancer 
contributes to more deaths than a combination of colon, breast, and prostate cancer. Lung 
cancer tends to be less common in those under 45 years (Hsu et al., 2012). There are 
differences in gender where a man can develop lung cancer at a rate of 1 in 13, and 




There are four distinct stages of lung cancer that range from mild to the most 
severe form (ACS, 2013). Stage IV lung cancer is an advanced form of the disease 
treated with chemotherapy or radiotherapy alone or in combination with another therapy. 
Therefore, due to the nature of the advanced stage of disease and the type of treatment 
involved, this research study was limited to Stages I, II, and III that were treated by tumor 
ablation or surgery. Stage I lung cancer is the earliest stage of lung cancer diagnosis and 
the one where long-term survival is the best; stage II lung cancer is defined as localized 
cancer where a tumor is present in the lung and may have metastasized to local lymph 
nodes, but has not spread further (NCI, 2012); non-small cell lung cancer is diagnosed as 
Stage III when the tumor has protracted beyond the lung and into other structures in the 
mediastinum or chest wall, directly or through the lymph nodes.  
Stage I 
Stage I lung cancer is the earliest stage of lung cancer diagnosis and the one 
where long-term survival is the best. About 30% of all lung cancer is at this stage or stage 
II (Henschke et al., 2006). Stage I lung cancer can present no symptoms; it can be 
detected when an individual at risk undergoes a computed tomography (CT) screening. 
Common symptoms may include persistent cough or recurrent episodes of pneumonia or 
bronchitis (NIH, 2010). Since the cancer does not spread easily, the major symptom 
associated with the disease is extreme fatigue, but weight loss or significant pain is 
usually absent (NCI, 2012). Surgery is usually considered the best treatment for stage I, 
but treatment also depends on where the tumor is located and the general health condition 
of the person. Three major types of surgery are performed, including video-assisted 




therapy (ACS, 2014; NCI, 2012). VATS are minimally invasive and may be used for 
those who cannot tolerate the traditional surgery such as older adults. In addition to 
surgery, other options for treatment of stage I lung cancer include radiation therapy and 
SBRT (ACS, 2014; NCI, 2015). Radiation therapy can be an option for patients with 
inoperable tumors and has proven successful enough to result in a cure (ACS, 2013). The 
third type of treatment is a new technique, SBRT and tumor ablation, which appears to be 
quite promising for those who are unable to go through surgery for stage I lung cancer 
(Pennathur et al., 2009). 
Stage II 
Stage II lung cancer is defined as localized cancer meaning that a tumor in the 
lung exists and has metastasized to local lymph nodes, but has not spread further (NCI, 
2012). Stage II lung cancer is subdivided into stages IIA and IIB. The National Cancer 
Institute (NCI, 2012) defined stage IIA lung cancer as a tumor which is 3 centimeters or 
smaller and cancer has not spread to nearby lymph nodes at the same side of the chest 
containing the tumor, whereas in stage IIB, cancer has spread to nearby lymph nodes on 
the same side of the chest as the tumor. The most prevalent symptoms in stage II lung 
cancer include a persistent cough, hemoptysis, shortness of breath, and pain in the chest 
or back. Symptoms such as weight loss and fatigue are less commonly identified with this 
stage of lung cancer as they are found in more advanced forms of lung cancer (NCI, 
2012). Once again, surgery is considered optimal for this stage of lung cancer. The three 
types of surgery for stage II lung cancer depend on the location of the tumor as well as 
general health concerns. Adjuvant chemotherapy or radiotherapy is recommended for 




The recurrence rate for localized cancer is in the range of 20-50%, while the 5-year 
survival rate for stage II lung cancer is 40-50% (Kelsey, Clough, & Marks, 2006). This 
evidence indicates that lung cancer is highly recurrent and difficult to survive depending 
on the tumor and general health condition of the patient. 
Stage III 
Non-small cell lung cancer (NSCLC) is diagnosed as Stage III when the tumor 
has protracted beyond the lung and into other structures in the mediastinum or chest wall, 
directly or through the lymph nodes (ACS, 2014; CDC, 2014). Cancer treatment becomes 
more difficult with increasing stage at diagnosis and greater severity (NCI, 2012). 
Compared to stages I and II, stage III lung cancer has a higher severity of disease and 
found near vital organs; thus, it is more difficult to treat with surgery (Lonardi et al. 
2000). Although the recommendation for treating stage III lung cancer is a combination 
of radiation therapy and chemotherapy, individualized treatment depends on performance 
status, prior weight loss and overall health (Lonardi et al., 2000). Thus, stage III lung 
cancer tends to be more challenging to cure compared to stages I and II because the 
tumor may be problematic or impossible to remove by surgery because of the severity of 
disease and the location near vital organs (Lonardi et al., 2000).  
Surgery and Tumor Ablation Treatments for Lung Cancer 
Many therapies such as surgery, embolization, drug therapy, chemotherapy, 
radiotherapy, and tumor ablation are conventional lung cancer treatments. Although these 
therapies have advantages and drawbacks in lung cancer treatment, surgery and tumor 




the two treatments selected for this study. Definitions of these lung cancer therapies or 
treatments have been discussed in Chapter 1.  
Surgery refers to an operative procedure for correction of deformities or a process 
that is used to treat lung cancer (ACS, 2015), and radiotherapy were documented in the 
literature to yield effective results (Chen & Johnston, 2002; Kelsey et al., 2006; Salati, 
Brunelli, Xiume, Refai & Sabbatini, 2009). Tumor ablation is a process whereby a needle 
applicator is placed into solid tumors using imaging guidance. This treatment option 
comprises of three major techniques (Simon and Dupuy, 2005). Applicators can deliver 
electric current (Radiofrequency ablation), electromagnetic energy (microwave ablation) 
or intense cold (cryoablation); although a relatively new modality, has achieved laudable 
results in the treatment of nonsurgical lung cancer patients by improving quality of life, 
survival, and overall prognosis (Dupuy et al., 2006; Jian, Dupuy, Cardarelli, Zheng, & 
DiPetrillo, 2003). Tumor ablation also reduces morbidity and mortality compared to 
surgery at a lower cost as well (Jian et al. 2003). Jian et al. described three older adult 
lung cancer patients who underwent radiofrequency ablation successfully; Belfiore et al. 
(2004) reported 35 successful radiofrequency ablation treatments that were performed 
with very encouraging results; and Tse et al. (2005) conducted a study in which 
transvenous catheter cryoablation was done successfully on atrial fibrillation (AF) 
patients. The study was conducted to determine the effects and the improvement of 
quality of life of the AF patients. Patients who had AF had significantly lower quality of 
life scores (Tse et al., 2005). However, patients who underwent successful cryoablation 
showed significant improvement overall and in five out of eight SF-36 quality of life 




Surgery and tumor ablation play a role in the treatment of lung cancer as indicated 
in the literature. Evidence indicated that the two lung cancer therapies proposed in this 
study were recognized for their effectiveness and the associated promising results 
(Balducci, 2003; Bircan et al., 2003; Dupuy et al., 2006). Owonikoko et al. (2007) 
conducted an analysis of lung cancer in older adults to determine differences in survival 
based on treatment modality. The distribution of cancer stage was not significantly 
different across age groups (less than 70, 70-79, and 80 and older), but the pattern of 
improved overall prognosis was observed across all stages. Between 1988-1997 and 
1998-2003 use of surgery increased while use of radiation decreased. Owonikoko et al.’s 
findings indicated that the respective therapies yielded good survival benefits. Of the 
316,682 patients eligible, 14% were 80 years or older, 33% were 70-79 years, and 53% 
below 70 years. Patients who were 80 or older were less likely to avoid surgery or 
radiation than those who were younger (47% compared to 28% and 19% for age 
subgroups greater or equal to 80 years, 70-79 years, and < 70 years, respectively). In 
general, prognosis for patients who had surgical therapy or radiation was similar among 
the three age groups (Owonikoko et al., 2007). In addition, there is an evidence of 
significant improvement in outcome for all groups with any treatment (Owonikoko et al., 
2007). However, evidence of disease progression was found in neither participant who 
received either therapy, surgery, nor radiation during the period 1998-2003 (Owonikoko, 
et al., 2007).  
Salati et al (2009) conducted a study of 279 patients who went through major lung 
resection where 98% of the patients survived the surgery. In this study, quality of life 




surgery measuring eight health concepts (bodily pains, physical functioning, vitality, 
physical role limitation, general health perception, social functioning and emotional role 
limitation, and mental health). The authors observed and reported that older adult lung 
cancer participants experienced a level of postoperative individual physical, emotional, 
and social well-being comparable to the mean of a general population of older adults 
(Salati et al., 2009). 
A study by Win et al. (2005) assessed 150 patients for consideration of lung 
cancer treatment using surgery. Twenty-one percent of patients were excluded for several 
reasons; not fit for surgery, refusal to go through surgery (12), or had more advanced 
disease at the final pathologic review (20). In addition, tumors found in eight were 
unresectable at the time of the surgery (open and closed thoracotomy), making it 
impossible to be studied further (Win et al., 2005). The study sample consisted of the 
remaining 110 patients (30% had borderline lung function). Evaluation using the EORTC 
QLQ-C30 included measuring emotional, social and cognitive functioning as well as 
physical role. The instrument also includes three symptom scales, one that measures pain, 
fatigue, nausea, and vomiting, a quality of life scale, as well as single items that assess 
additional symptoms (Win et al., 2005). The supplementary lung module LC 13 was also 
used to measure lung cancer associated symptoms that included hemoptysis, cough, 
shortness of breath, chest or body pain, and chemotherapy or radiotherapy side effects 
that may include peripheral neuropathy, sore mouth, dysphagia, and hair loss (Win et al., 
2005). Before the 110 patients underwent surgery, both instruments were administered 
and at 1, 3 and 6 months postoperatively (Win et al., 2005). The authors reported that 




compared with a general lung cancer population (Win et al., 2005). Furthermore, the 
short-term surgery for lung cancer had a short lived negative effect on quality of life that 
dissipated at 6 months post-surgery. Unfavorable HRQL scores did not predict poor 
surgical outcome, defined as death or major complication, although poor surgical 
outcome was correlated with a worse postoperative quality of life at 6 months (Win et al., 
2005).  
Radiofrequency ablation reduces morbidity and mortality as compared to surgery 
and together with its lower cost makes it suitable for older adult lung cancer patients to be 
able to opt for such therapy (Dupuy et al., 2006; Jain et al., 2003). In addition, palliative 
care symptoms associated with quality of life such as cough, hemoptysis, shortness of 
breath, and pain were reduced with radiofrequency ablation (Jain et al., 2003). To 
determine the importance of tumor ablation as an upcoming viable lung cancer treatment 
therapy, Jain et al. (2003) described how three patients (ages 78, 61, and 65 years old) 
were treated with combined radiofrequency ablation and brachytherapy guided by 
computer tomography. The authors stated that the three patients tolerated the combination 
therapy well (Jain et al., 2003). The authors determined that percutaneous radiofrequency 
ablation in conjunction with brachytherapy is feasible and suggested that a minimally 
invasive combination modality can be used to eradicate local tumors (Jain et al., 2003). In 
addition, radiofrequency ablation, a new therapy used to remove lung tumors, could 
provide significant advantages to nonsurgical candidates who undergo lung cancer 
therapies (Jain et al., 2003). Jain et al. (p. 712) therefore reported that “percutaneous 
image-guided tumor ablation with radiofrequency is an expanding minimally invasive 




In a study conducted by Belfiore et al. (2004), 35 successful radiofrequency 
ablation treatments were performed where the objective was to investigate the safety, 
effectiveness, technical feasibility/possibility, and possible complications of palliative 
CT-guided radiofrequency ablation of unresectable primary pulmonary malignancies. 
Complications included were three cases of minor pneumothorax, five cases of sputum 
cruentum, and three asymptomatic pleural effusions in the periprocedural period 
(Belfiore et al., 2004). The authors suggested that radiofrequency ablation could be 
successful for unresectable lung cancer in addition to radio- or chemotherapy (Belfiore et 
al., 2004). 
Clinical and treatment-related data regarding 129 consecutive percutaneous 
radiofrequency ablation treatment sessions for 100 patients with inoperable lung tumors 
were analyzed for risk factors following procedures that included pleuritic chest pain, 
overall morbidity, pleural effusions, hemoptysis, pneumothorax, and chest drain 
requirement (Zhu, Yan, Glenn, & Morris, 2009). Researchers found that for lung tumors 
radiofrequency ablation was considered as a safe procedure with low incidence of 
complications and that better understanding of any risk factors because of adverse events 
could help in preventing and recognizing any potential complications (Zhu et al., 2005).  
Tse et al. (2005) conducted a study in which transvenous catheter cryoablation 
was done on atrial fibrillation patients. This study was conducted to determine the effects 
and the improvement of quality of life of the atrial fibrillation patients. Quality of life was 
assessed using Medical Outcomes Study Short Form 36 and Symptom Checklist at 
baseline and 3-months post treatment. Participants were compared with sex-age matched 




lower quality of life scores overall and five out of eight subscales of SF-36 compared to 
the sex-age matched control group (p < 0.05). On the other hand, patients who had 
successful cryoablation showed significant improvement in overall and in five out of 
eight subscales of SF-36. Quality of life scores have significantly increased as compared 
with the baseline (p < 0.05; Tse et al., 2005). However, at the 3-month follow-up, there 
was a significant reduction in both symptom frequency and symptom severity scores as 
compared with the baseline scores (p < 0.05; (Tse et al., 2005). 
The benefit of selecting which treatment modality yields positive outcomes for 
both the patient and the clinician had been elaborated in the literature. Several authors 
suggest that positive outcomes will better assess the prevailing symptoms suffered by the 
patient as well as the relative importance given by both the patient and the provider 
(Balduyck et al., 2007; Cella et al., 1995; Montazeri et al., 2003; Pasetto et al., 2007; 
Sloan et al. 2012). This will help in formulating better plan for best treatment strategy. 
The Aging Process and Lung Cancer among Older Adults 
According to the 2014 U.S. Census, the population of older adults grew at a faster 
rate than the younger population indicating that the older adult population is one of the 
fastest-growing populations in the United States (U.S. Census Bureau, 2014). The 65 and 
over population was 43.1 million persons (13.7% of the general population) and the 
population aged 65 and over grew at a faster rate of 15.1% than the population under age 
45 (Howden & Meyer, 2011; Ortman, Velkoff, & Hogan, 2014; U.S. Census Bureau, 
2014). Furthermore, the older adult population in the U.S. is estimated to double from 35 
million to 72 million by the year 2030 and to 83.7 million by 2050 (Ortman et al., 2014; 




than half of all non-small cell lung cancer patients are older than 65 years of age, whereas 
about one-third are older than 70 years old (Owonikoko et al., 2007). Lung cancer 
continues to be a global problem and affects both young and old, but the incidence of the 
disease has decreased for individuals aged 50 and younger while it has increased among 
70 years old and above (Gridelli et al., 2005). Age is known to be associated with 
increased risk for surgical and radiation complications, but surgery and radiation therapy 
are beneficial to older adult lung cancer patients (Balducci, 2003). 
The selection of optimal treatment for older adult lung cancer patients face 
medical challenges such as chronic obstructive pulmonary disease and emphysema, and 
treatment side effects as well as physiologic challenges (Frick et al., 2007; Wilders, 
2006). Anxiety and depression in functional status as well as challenges in lean body 
mass and marrow reserve or drug clearance were cited as examples (Gridelli et al., 2007). 
Older adult patients may be denied potentially beneficial treatment and participation in 
clinical trials solely because of old age and because medical professionals have the 
perception that those older adults are too frail to withstand any type of lung cancer 
treatment (Owonikoko et al., 2007). However, the process of aging is multidimensional, 
and assessment needs to be comprehensive of function, comorbidity, and personal and 
social resources (Balducci, 2003). Owonikoko et al. (2007) stated that age alone might 
not be a significant prognostic factor in lung cancer treatment. His argument stemmed 
from the fact that the European Organization for Research and Treatment Center 
(EORTC) reported that increase in age is a good prognostic factor for response to some 




Advances in medical science and technology have resulted in enabling more 
people to survive into old age, nevertheless, with longer life spans there has been an 
increased incidence of acquiring pathologies in cancer (Gridelli et al., 2007). Hence, the 
frequency with which older adults develop carcinogenic pathologies in the lung is a 
prevalent and societal burden (Gridelli et al., 2007). The above result as an opinion 
confirmed that older adult lung cancer patients have the potential to survive if they adhere 
to a standard course of daily activities such as exercise, eating healthy, and following the 
ADLs in addition to responding to their medical appointments.  
Health-Related Quality of Life in Lung Cancer Patients 
Quality of life studies can be feasible, useful, and beneficial in cancer studies. 
Previous quality of life studies indicated comprehensive assessment and self-report 
methodology from the responders because they allowed the patients to answer questions 
and discussed issues that related to their condition and well-being (Di Maio & Perrone, 
2003). The answers obtained help medical providers have greater understanding in 
evaluating the patients’ problems to offer better plan for treatment (Di Maio & Perrone, 
2003).  
Some clinical trials were conducted to show how useful HRQL is in treating 
NSCLC (Hirsh, 2013; Lemonnier et al., 2014; Wintner et al., 2013). A clinical trial 
comparing NSCLC and HRQL was conducted by Lemonier and colleagues to show the 
predictive role of HRQL on NSCLC after initial treatments on survival (Lemonnier et al., 
2014). This study was done to determine whether there is correlation between perceived 
health in HRQL and initial treatment for NSCLC patients. Researchers found that there 




treatment of NSCLC and better survival prognosis (Lemonnier et al., 2014). The study 
emphasized the importance the researcher of the present study seeks to address, whereby 
HRQL assessment done on lung cancer patients at initial treatment would benefit older 
adult lung cancer patients. 
According to Balduyck et al. (2007) self-administered quality of life 
questionnaires in oncological research are becoming an important part of evaluation 
criterion for clinical decision-making, thereby stressing the importance of its future use. 
An important aspect of HRQL instrument’s validity is responsiveness to change over 
time as well as performance status rating, which is commonly used as an indicator for 
participant functional status in a clinical trial (Cella et al., 1993). The evaluation of 
HRQL has become important in lung cancer patients because of high-symptom burden 
and severe morbidity (Anant et al., 2005). HRQL measures also help providers and 
patients to compare different treatment modalities in lung cancer, thus allowing for 
selection of the appropriate modality (Anant et al., 2005). 
Researchers recognized that quality of life needs is a key goal when considering 
treatment options of older patients with lung cancer (Cella et al., 1995; Hollen et al., 
1995). However, apart from Cella et al., Balduyck et al. (2007), Hollen et al. (1995), and 
Pasetto et al. (2007), who have done a few studies in this area, a limited number of 
studies have specifically focused on the topic (Braun et al., 2011; Damm et al., 2013; 
DiMaio & Perrone, 2003). Reiterating the importance of quality of life DiMaio and 
Perrone (2003) and Braun et al. (2011) reported that the assessment of HRQL in older 
adult patients with lung cancer was areas of contention in research especially the 




older adult patients later was determined to depend on the sound judgment bordering the 
effects of both quantity and quality of life (Braun et al., 2011). Damm et al., reported on 
the satisfactory quality of life in lung cancer, stated that as the number of treatment 
alternatives increases, the need for comparable assessments of HRQL parameters grows 
as well. The area has not been fully studied and therefore the authors postulate more 
assessment in the field. This is one of the reasons for designing the present study. There 
is also a gap in this field of research; hence, there is a need for assessment of HRQL in 
lung cancer of older adults.  
The role of HRQL assessment in lung cancer research is promising, but many 
methodological problems such as the reliability of the survey responses received from 
older adults need to be resolved to allow the best use of potential utility of instruments 
(Hirsh, 2013; 2014; Lima et al. 2011). In addition, HRQL assessment in clinical practice 
may be beneficial to older adult patients and could provide good rapport or better 
communication between the patient and clinician, hence, the need for more application of 
properly selected instruments (Lemonnier et al., 2013). The emphasis of clinical trials 
specifically dedicated to older adult participants needs to be stressed, because systematic 
HRQL assessment in clinical practice using self-reported questionnaires have proven 
feasible and useful (Di Maio & Perrone, 2003; Hirsh, 2013; Lemonnier, 2013). This has 
given prognostic power for survival of patients by allowing for the discussion between 
the clinician and the lung cancer patient about the answers given on the questionnaires 
(Di Maio & Perrone, 2003). 
To support the importance of HRQL assessment, the following studies are 




quality of life evolution after lung cancer surgery in 100 patients using the instruments 
EORTC QLQ-C30 and EORTC QLQ-LC13. Reliability and validity of these two 
instruments was previously confirmed in international studies (Balduyck et al., 2007). 
The study focused on role functioning, emotional functioning, physical functioning, 
cognitive functioning, social functioning, and global quality of life, and was a first step in 
evaluating intermediate to long-term quality of life evolution in participants undergoing 
pulmonary surgery (Balduyck et al., 2007). Questionnaires were given to participants to 
complete 1 day before surgery and at 1, 3, 6, and 12 months after surgery. Thirteen 
women and 87 men were selected to participate in the study. At baseline, questionnaire 
response rate was 100%, while at 1, 3, 6, and 12-month response rates dropped to 71%, 
77%, 83% and 76%, respectively (Balduyck et al., 2007). Comparison of quality of life 
and shortness of breath (dyspnea), coughing, general pain, thoracic pain, and shoulder 
dysfunction were obtained using EORTC QLQ-C30 (Balduyck et al., 2007). The authors 
found that quality of life in lung cancer patients who underwent surgery tended to 
diminish significantly as the disease progressed. This was mostly associated with cancer 
symptoms like fatigue, chronic pain, and weakness. They also postulated that those 
symptoms were linked to recurrent disease, which was a determinant of post-operative 
quality of life (Balduyck et al., 2007).  
Montazeri et al. (2004) also conducted a prospective population-based study in 
Glasgow, Scotland on quality of life in lung cancer participants to determine whether the 
knowledge about lung cancer diagnosis could affect quality of life. In this study, 129 lung 
cancer participants were interviewed to determine their knowledge of the disease at 




and 99 (77%) participants did not know about their diagnosis. Montazeri et al. (2004) 
found that knowledge of diagnosis of lung cancer did not affect participants’ responses to 
the quality of life questionnaire. According to the authors, their assertion is because 
regardless of awareness of lung cancer diagnosis, participants responded in a comparable 
manner on most measures or domains studied, typically the psychosocial domains 
(Montazeri et al., 2004). This assumption was assessed before, during, and after the 
research. Montarezi's study showed that if participants know about their disease (lung 
cancer), they will be more proactive to look at quality of life dimensions. Participants 
who were more proactive in their quest for information on quality of life dimensions may 
relate to the present study in a way that they will have knowledge about which therapy to 
opt for as well as the benefits of healthcare cost associated with their disease as stated in 
the change of social impact. This research may also help reduce health costs that may be 
incurred by patients by engaging in and adhering to HRQL activities.  
Socioeconomic status plays a key role in an individual’s behavioral life. As a 
result, Montazeri et al. (2003) prospectively studied the association between quality of 
life and socioeconomic status of lung cancer participants. Out of 129 participants, 82 
participants completed both baseline and follow-up measures, including physical 
mobility, energy, role functioning, physical functioning, and breathlessness (Montazeri et 
al., 2003). Fifty-seven percent of participants came from low socioeconomic status, had 
more health problems, were less functioning, and had more symptoms as compared to 
affluent participants (Montazeri et al., 2003). The authors found that patients with lower 
socioeconomic status had more health problems, less functioning and global quality of 




al., 2003; Ma & McGhee, 2013; Mielck, Vogelmann, & Leidi, 2014). Ma and McGhee 
stated that economic hardship and HRQL are strongly related, in that more attention 
should be placed on subjective SES indicators when dealing with HRQL. Similarly, other 
authors such as Cassedy et al. and Mielck et al. reported that having a clear idea of 
relationship between SES and HRQL will help researchers make unbiased assessments of 
results obtained from studies, which could help develop more effective interventions to 
improve HRQL. This could show that socioeconomic status may play key role in HRQL 
assessment. It might also test the confounding that people with low socioeconomic status 
might have problems accessing good and quality medical care. 
Salati et al. (2008; 2009) assessed HRQL in older adult patients after major 
surgical resection for lung cancer. The purpose was to determine the difference observed 
in younger patients to provide additional information that could help to clarify the role of 
surgery in high-risk group older adult lung cancer patients. Salati and colleagues (2008) 
observed that few lung cancer studies have focused on participants reported outcomes 
such as quality of life, thus limiting the capability of surgeons to exhaustively counsel 
patients about their perioperative risk and residual function (Salati et al. 2008; 2009). 
Resuming an acceptable daily lifestyle is a crucial factor that may critically influence the 
decision to undergo lung resection (Salati et al., 2008; 2009).  
Quality of life was measured using the administration of Short Form-36 Health 
Survey (Salati et al., 2008; 2009). The survey was used to assess physical role limitation, 
physical functioning, physical pain, health perception, social functioning, vitality, 
emotional role limitations, and mental health (Salati et al., 2008; 2009). In the study, 




patients, mean age = 75 years) had worse exercise performance on the stair climbing test 
(p < 0.0001) as compared to younger patients (133 patients, mean age = 59.4 years). It 
appears that although the patients were conscious of their poorer physical conditions, 
they were also more prepared to be sick and to face the challenge of cancer and the 
treatment associated with it. The authors reiterated the importance of providing reliable 
information on older adult lung cancer patients’ psychological and physical function. The 
patients with a limited cardiorespiratory function remained in the balance between 
oncological radicality and the prospect of an inadequate quality of life, which may have 
ethically influenced the decision to proceed to surgery (Salati et al., 2008). This means 
that although older adult lung cancer patients were fearful about their diagnosis, they 
were also conscious about the fact that something had to be done about the disease to 
increase their health performance status. Finally, the authors noted that measures of 
quality of life reflected patients’ perspectives and these measures could be affected by 
other factors associated with emotion such as social support, the radicalness of the 
procedure, and satisfaction with care. Therefore, there is the need for further studies to 
account for social support and degree of satisfaction factors on postoperative residual 
quality of life. Patients after the postoperative procedure were to make sure that there 
were family members to take care of them, help them go through their medical 
appointments, and can do their ADLs or house chores. 
Pain is a subjective factor and its measurement depends on the individual. In 
terms of lung cancer treatment, pain is more likely to be associated with surgery as 
compared to tumor ablation; hence, pain could be measured as part of the quality of life 




needed to confirm their results in a larger population and to identify strong predictors of 
residual quality of life that may further assists surgeons and/or medical practitioners in 
counseling their patients as well as planning perioperative physical and psychological 
supportive programs which will help improve lung cancer patients’ health perception 
(Salati et al., 2008; 2009).   
A randomized trial was done by the Elderly Lung Cancer Vinorelbine Italian 
Study Group (ELVIS) to determine the effects of vinorelbine—a semisynthetic vinca 
alkaloid on quality of life and older patient survival who had advanced non-small cell 
lung cancer (ELVIS, 1999; Winton et al., 2005). This study reinforces the importance of 
the role quality of life plays in the survival of older adult patients with non-small cell 
lung cancer, even though chemotherapy was not particularly studied. The study included 
patients 70 years of age and older, stage IV or IIIB NSCLC, who were ineligible for 
radiotherapy (ELVIS, 1999); patients 65 years and older with completely resected T2N0, 
T1N1, T2N1 NSCLC (Winton et al., 2005). EORTC questionnaires (QLQ-C30 and 
QLQ-LC13) and the Cox regression model, stratified according to nodal status (Winton 
et al., 2005) was used to analyze the results by fitting a linear mixed model for each 
quality of life scale. Data from 161 and 482 (including 242 patients and 240 observation) 
patients were analyzed respectively. The investigators found out that patients who were 
treated with vinorelbine scored better than control patients on quality of life functioning 
scales and reported fewer lung cancer-related symptoms. However, they found that these 
patients reported worse toxicity-related symptoms, such as constipation, nausea, 
vomiting, hair loss, and peripheral neuropathy (ELVIS, 1999). Cognitive function was 




In terms of symptom scales and items, results obtained from the participants treated with 
vinorelbine were more encouraging than from the control patients for pain and shortness 
of breath (dyspnea) (ELVIS, 1999). The investigators concluded that vinorelbine may 
have improved survival of older adult patients with lung cancer and had a low enough 
level of toxicity. Patients remained free of disease that had completely resected early-
stage NSCLC, and vinorelbine may have improved overall quality of life (ELVIS, 1999; 
Winton et al., 2005).  
LCSS is another HRQL tool which is responsive to changes in performance status 
signifying the different scores for individuals with different states of disease. In a study 
conducted using LCSS with 207 NSCLC patients and 21 observers, Hollen et al. (1995) 
reported a comparison with the Karnofsky scale indicating that results from the study 
supported the premise that the primary factors assessed by LCSS (physical and functional 
domains) were predictors of quality of life for those with lung cancer who used some sort 
of therapy. The authors reported the Cronbach’s alpha coefficients were 0.82 for the 
participant scale, 0.71 for the average symptom burden subscale, and 0.75 for the 
observer scale (Hollen et al., 1995). The authors concluded that measurement of less 
relevant factors may be assessed in less depth through summation items and that the 
explained variance of quality of life (about half) by the LCSS is reasonable for evaluation 
of new therapies such as tumor ablation (Hollen et al., 1995). 
Generally, the above studies have shown how HRQL in lung cancer could be 
important for older adults such that the possibility to resume an acceptable daily lifestyle 
becomes a crucial factor and may critically influence the decision of the elders 




on older adult lung cancer patients’ physical well-being and functioning well being as 
well as patients who have limited cardiorespiratory performance. Therefore, care must be 
taken when considering the lung cancer therapy. Although the conceptual model of 
quality of life used as the guide for this study includes both a physical and functional 
dimension, the LCSS instrument only measures physical well-being, symptom distress 
and global quality of life, but not the functional dimension. The functional dimension is 
measured by assessing activities of daily living. It was mentioned previously that these 
are beyond the scope of this study.  
Health-Related Quality of Life Tools 
There are several tools described in the literature to measure quality of life and 
HRQL and to some degree these may be interchangeable. The instruments described 
below are tools that have been used in HRQL assessment. They have been tested and 
found to be valid and reliable as well as conforming to international standards. These 
tools were already described briefly in Chapter 1 by domain tested (Table 1) and type of 
treatment (Table 2). The researcher of the present study aims to fill the research gap in 
assessing HRQL in physical function among older adults being treated with either 
surgery or tumor ablation using the LCSS questionnaire. The LCSS tool is short and not 
time consuming. It offers the participants relatively shorter time to complete the survey as 
compared to the other tools. Participants generally will use about 8 minutes to complete 
the survey while EORTC and FACT-L use about 11-15 minutes to complete. The review 
presented in the next sections encompasses a broader assessment than physical function 
and has a focus on the psychometric properties of the Functional Assessment (FACT-




Functional Assessment of Cancer Therapy—Lung 
The Functional Assessment of Cancer Therapy-Lung (FACT-L) scale is a 44-item 
instrument, which measures multidimensional quality of life. It can be used in clinical 
trials. It is a tool that was developed in 1987 by David F. Cella and colleagues and has 
been used since then as a testing and comprehensive measurement system for HRQL for 
lung cancer patients. It measures social and emotional well-being, physical, and 
functional status of the patient (Cella et al., 1995; Browning, Ferketich, Otterson, 
Reynolds, & Wewers, 2009; Busarik et al., 2013). The reliability and validity (multiple 
studies had been conducted to obtain same or almost same results) had been published 
using international standards (Cella et al., 1995; Browning et al., 2009; Busarik et al., 
2013). The construct validity and reliability of FACT-L to measure quality of life has 
been done over a period since 1987 by Cella and colleagues using factor analysis (Tulsky 
et al., 1993). This has confirmed hypothesized multidimensional structure of the 
instrument and patterns of correlation coefficients. Correlations had been predicted 
between FACT-L and other instruments such as FACT-General (FACT-G), Functional 
Living Index-Cancer (FLIC), and Lung Cancer Subscale (LCS). The correlation between 
FACT-G and FLIC is 0.58; between the FACT-L and FLIC is 0.60; and among FACT-G, 







Reliability and Validity Coefficients among Lung Cancer Quality of Life Measures 
Instrument 
 











LCS 0.66 0.66 - - 
α coefficient - - > or = 0.70 > or = 0.70 
 
Source: Cella et al. (1995). Reliability and validity of the functional assessment of cancer 
therapy—lung (FACT-L) quality of life instrument. Lung Cancer, 12, 199-220; 
Balduyck, et al. (2007) Quality of Life evolution after lung cancer surgery: a prospective 
study in 100 patients. Lung Cancer; 56, 423-431. 
FLIC--Functional Living Index-Cancer 
LCS--Lung Cancer Subscale 
 
EORTC QLC-30 and LC-13 
In 1986, an organization called European Organization for Research and 
Treatment of Cancer started a research program to “develop an integrated, modular 
approach for evaluating the quality of life of patients participating in international clinical 
trials” (Aaronson et al., 1993, p. 365). This group conducted two international field 
studies to evaluate how practical, reliable, and valid the core questionnaire (EORTC 
QLQ-C30) and a supplemental 13-item lung cancer-specific module, the EORTC QLQ-
LC13 (Balduyck et al., 2007; Damm et al., 2013). The organization reported the 
reliability and validity of their results by using 30 core questions, which came to be 
known as EORTC QLQ-C30 (Aaronson et al. 1993). The EORTC QLQ-C30 is a self-
rating questionnaire that consists of 30 questions and uses nine multi-item scales. It 
includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom 




that assess additional symptoms such as constipation, dyspnea, sleep difficulties, and 
diarrhea (Aaronson et al., 1993, p. 366; Wintner et al., 2013). The purpose of this 
instrument is to determine self-reported methodology from patients. Its reliability and 
validity have been confirmed in international studies (Balduyck et al., 2007; Damm et al., 
2013).  
To determine the reliability and validity, the questionnaire was administered to 
305 patients from 13 countries, who had nonresectable lung cancer. Variables included 
weight loss, disease stage, performance status, and treatment toxicity (Aaronson et al., 
1993). On the average, the minimum time required to complete the questionnaires where 
no assistance was needed by most patients was 11 minutes (Aaronson et al., 1993). Data 
supported the hypothesized scale structure of the questionnaire except for role 
functioning, such as work and household activities which did not meet the minimal 
standards for reliability (Cronbach’s ά ≥ 0.70) (Aaronson et al., 1993). Validity was 
based on moderate interscale correlations, components of quality of life constructs 
including the functional and symptom measures, weight loss, as well as treatment toxicity 
(Aaronson et al., 1993). In addition, performance status, physical, and role functioning, 
global quality of life, fatigue, nausea, and vomiting results provided statistically 
significant changes for lung cancer patients (Aaronson et al., 1993). 
According to Aaronson et al. (1993), reliability and validity of the questionnaire 
were highly consistent among the three groups of individuals from Northern Europe, 
English-speaking countries, and Southern Europe. In addition, it was shown that the 




in cancer patients from many distinct cultural clinical settings (Aaronson et al., 1993; 
Balduyck et al., 2007; Damm et al., 2013).  
EORTC Quality of Life Questionnaire-Lung Cancer 
The lung cancer specific module LC13 (EORTC QLQ-LC13) is a supplementary 
questionnaire to the EORTC QLQ–C30 module designed for use among patients 
receiving treatment in lung cancer (Balduyck et al., 2007). The module was comprised of 
multi-item and single-item measures of lung cancer-associated symptoms (Balduyck et 
al., 2007; Damm et al., 2013). The module was administered to lung cancer patients with 
nonresectable tumors. The purpose was to determine self-reported questionnaires from 
participants who have been diagnosed with lung cancer (Balduyck et al., 2007; Damm et 
al., 2013). The module contained 13 questions that assessed lung cancer as well as related 
symptoms like side effects of chemotherapy or radiotherapy, cough, dyspnea, 
hemoptysis, site-specific pain, peripheral neuropathy, dysphagia, and alopecia (Balduyck 
et al., 2007). Its reliability and validity have also been confirmed in international 
standards (Balduyck et al., 2007). It is scored in the same manner as EORTC QLQ-C30 
described above.  
Participants were gathered from 17 countries and submitted the questionnaire once 
while undergoing treatment. From these participants 883 completed the questionnaire 
before treatment and 735 completed it once during treatment (Bergman et al., 1994). 
Cronbach’s alpha coefficient greater or equal to 0.70 was reported to emphasize that the 
study supported the scale structure (Bergman et al., 1994). However, items that pertained 
to pain did not form a scale that was reliable for group comparisons (Bergman et al. 




of the 23 multi-item dyspnea scales (Bergman et al., 1994). Results from international 
field testing supported the EORTC QLQ-LC13 as a valid instrument that is useful for 
measuring disease- and treatment-specific symptoms among patients with lung cancer 
who participate in clinical research in combination with the EORTC core QL 
questionnaire (Bergman et al., 1994). The patterns of these correlations to substantiate the 
validity and reliability of the tool are seen in Table 1. 
Lung Cancer Symptom Scale 
The Lung Cancer Symptom Scale (LCSS) is a quality of life instrument used to 
evaluate physical and functional domains of individuals diagnosed with lung cancer at a 
specific site, but devoid of treatment toxicity (Hollen et al., 2005). LCSS is a HRQL tool 
that is responsive to changes in performance status signifying the different scores for 
individuals with different states of disease (Hollen et al., 2005; Hollen et al., 2012; Iyer, 
Taylor-Stokes, & Roughley, 2013). The advantage of the LCSS instrument is its 
simplicity (Earle, 2004). This scale consists of two symptoms scales administered to 
patients and health professionals completing a form as observers. The patient scale 
consists of nine items. Six of these items measure symptoms for lung cancer that include 
fatigue, appetite loss, dyspnea, cough, hemoptysis, and pain. Three summary items that 
measure total symptom distress include normal activity status and overall quality of life 
(Hollen et al., 2005; Iyer et al., 2013). The primary developers of the LCSS were Patricia 
Hollen, Richard J. Gralla, and Mark G. Kris (1995). In developing this scale, the purpose 
was to develop a tool for measuring quality of life to ease patient and staff in serial 




dimensions most likely to be influenced by therapeutic interventions and evaluates other 
dimensions globally (Iyer et al., 2013).  
The LCSS focuses on physical and functional aspects of the participants (Iyer et 
al., 2013), which is what I sought to assess in the present study. The LCSS measures 
physical functioning through six symptoms of lung cancer that include fatigue, dyspnea, 
appetite loss, cough, hemoptysis, and pain. Three summary items measure total symptom 
distress, normal activity status, and overall quality of life experience (Hollen et al., 2005; 
Hollen et al., 2012; Iyer et al., 2013). This study assesses eight of the nine physical 
quality of life dimensions of the LCSS. However, the normal activity status component is 
not measured in this study because it requires measurement beyond the 3-month period. 
The scoring system of the LCSS is measured as scores of equal lengths of line 
marked by patient and an average of the aggregate score of all nine items is used for a 
total score” (Hollen et al., 1995, p. 6; Appendix F). In addition, a subscoring system is 
used to determine the mean of all 6 major symptoms that make up the average symptom 
burden index. Specific areas of change can be represented by a quality of life aggregate 
of several items or individual items. The LCSS was tested in over 1000 patients with lung 
cancer in about six different published studies (Browning et al., 2009; Gralla et al., 2009; 
Hollen et al., 2005; Hollen et al., 2012; Iyer et al., 2013). In a study with 207 NSCLC 
patients and 21 observers, Hollen and colleagues reported that the Cronbach’s alpha 
coefficients were 0.82 for the patient scale, 0.71 for the average symptom burden 
subscale, and 0.75 for the observer scale (Hollen et al. 1995).  
Comparison of the LCSS with the Karnofsky scale indicated that the LCSS is 




differences in scores (Hollen et al. 1995). The results from that study supported the 
premise that the primary factors assessed by LCSS, the physical and functional domains, 
are important predictors of quality of life for individuals with lung cancer undergoing 
some sort of therapy (Hollen et al., 1995). Therefore, the authors concluded that 
measurement of less relevant factors may be assessed in less depth through summation 
items and that the explained variance of quality of life (about half) by the LCSS is 
reasonable for evaluation of new therapies (Hollen et al., 1995). The concept of 
minimally important difference (MID) for HRQL instruments is equated with half of the 
variance explained in a review of 38 studies (Norman, Sloan & Wyrwich, 2003). The 
threshold of discrimination for changes in HRQL for chronic disease appears to be about 
half of the standard deviation (Norman, Sloan & Wyrwich, 2003).  
The LCSS was also validated with patients diagnosed with mesothelioma (Hollen 
et al., 2004). To test the conceptual model of the instrument, LCSS-meso, 495 patients 
undergoing chemotherapy with unresectable malignant pleural mesothelioma were 
randomized to undergo two clinical trials with pemetrexed (Hollen et al., 2004). Poisson 
regression was used for predictive value of physical symptoms, symptomatic distress, 
activity level, and global quality of life at baseline, 40 days, and 82 days post-treatment 
(Hollen et al., 2004). More than 85% of the patients reported pain, dyspnea, fatigue, and 
appetite loss (Hollen et al., 2004). The researchers concluded that for both mesothelioma 
and lung cancer, most of the symptoms within the LCSS model supported the use of 
LCSS as a "sensitive instrument for serial measurement during clinical trials involving 




Browning et al. (2009) examined both the FACT-L and LCSS as instruments to 
assess quality of life in recently diagnosed lung cancer patients and found both were 
psychometrically valid instruments and widely used in literature. However, I found the 
LCSS was better suited for the present study because it measures physical and functional 
domains of quality of life, while the FACT-L includes social and emotional domains as 
well. Browning et al. reported on the internal consistency and validity of both instruments 
from data collected from a larger study examining smoking behavior in newly diagnosed 
patients. Descriptive statistics were calculated for internal consistency on the FACT-L 
and LCSS by estimating Cronbach’s alpha coefficients and Pearson correlation 
coefficients between the two scales. Browning et al. found that internal consistency 
coefficients demonstrated good reliability for both scales and both instruments 
demonstrated a strong correlation, suggesting good convergence validity. 
Gralla et al. (2009) also used the LCSS to assess the impact of neoadjuvant 
therapy on quality of life and noted that the LCSS was a validated instrument designed 
for clinical trials and patient management. Symptoms in this study were measured on a 
100-mm visual analogue scale (VAS) and scores ranged from 0 to 100 (0 meaning no 
impairment, 100 most impairment). Gralla et al. noted that this scale has been shown to 
have good psychometric properties and used the patient-based LCSS, which included 
three symptoms from a thoracic subset (i.e., cough, dyspnea, and hemoptysis), three from 
a general subset (anorexia, fatigue, and pain), and three summary items (symptom 
distress, interference with daily activities, and global quality of life). 
Nowak et al. (2004) reporting from a study conducted by Vogelzang et al. stated 




improvements with pemetrexed and cisplatin as compared with cisplatin alone. Similarly, 
in a systematic literature review looking at HRQL instruments, Damm et al. (2013) 
reported the need for LCSS as one of the tools for measuring HRQL in lung cancer, even 
though it has been used in a few studies as compared to EORTC LC 13.  
 LCSS has been used in other studies after its development by Hollen et al. as well. 
For example, Garces et al. (2004) conducted a study using the tool to find relationship 
between cigarette smoking and quality of life after lung cancer diagnosis. The instrument 
was mailed to 1,506 patients between the years 1999 and 2002, where LCSS scores were 
compared among diverse groups of cigarette smokers through univariate independent 
group testing and multivariate linear models (Garces et al., 2004). The results from the 
study showed that seven of the individual LCSS quality of life components (i.e., appetite, 
fatigue, cough, shortness of breath, lung cancer symptoms, illness affecting normal 
activities such as walking, and overall quality of life) were statistically and clinically 
significant (p < 0.001) and were different between nonsmokers and persistent smokers. 
Researchers also found no significant differences in pain or hemoptysis (Garces et al., 
2004). The authors concluded that the relationship between smoking status and quality of 
life was supported by the correlational study, and that persistent cigarette smoking status 
and quality of life after a lung cancer diagnosis impacted quality of life scores negatively 
(Garces et al., 2004). 
 The LCSS was used in another therapy involving quality of life and non-small 
cell lung cancer where pemetrex maintenance was conducted on patients (Belani et al., 
2012). Researchers found that through LCSS the therapy significantly improved overall 




cancer as compared to placebo (Belani et al., 2012). Four cycles of platinum-based 
induction therapy were given to 663 patients with stage IIIB or stage IV NSCLC between 
March 2005 and July 2007. Patients completed the LCSS from baseline, after each cycle, 
and at post-discontinuation (Belani et al., 2012). The authors reported that baseline 
characteristics to include LCSS score were well balanced between groups, which were 
low, thereby, indicating low symptom burden for patients without disease progression 
after completion of first-line treatment (Belani et al., 2012). According to the authors, the 
results proved that with pemetrexed maintenance therapy there was amelioration in 
overall and progression-free survival and treatment of this type can be helpful for patients 
with advanced NSCLC (Belani et al., 2012) 
LCSS is the preferred choice of tool for the present study because of its high 
acceptance rate by patients and professionals, the rapid completion time, ease of use, and 
strong psychometric properties it possesses (Hollen et al., 2012). In addition, the LCSS is 
a simplified version among the discussed instruments and the tool is more user-friendly 
and beneficial to the older participants than the other two instruments FACT-L and 
EORTC QLQ 30 and LC-13, which consist of many questions and take longer time (11-
15 minutes) to answer. The ease with which the participants might find the tool together 
with shorter time to answer the questionnaires emphasize the importance of the choice of 
LCSS as the appropriate tool for this study in the HRQL assessment of lung cancer.  
There are equally other studies such as EORTC studies and LCSS whose validity 
and reliability have been confirmed and conformed to international standards. These 
studies have become useful in quality of life studies and are specific for lung cancer. The 




and symptoms scales (Balduyck et al., 2007), while the LCSS looks at six measuring 
major symptoms for lung cancer (appetite loss, fatigue, cough, dyspnea, hemoptysis, and 
pain) and three summary items related to total symptom distress, normal activity status, 
and overall quality of life (Hollen et al., 2005). The EORTC and LCSS instruments have 
reported extensively on quality of life studies and other researchers have used these tools 
in their studies to find the viability and the usefulness of them in quality of life studies. 
For example, Nowak et al. (2004) used EORTC in their studies to find the feasibility and 
the validity of results in quality of life studies in chemotherapy for pleural mesothelioma. 
Salvo et al. (2009) examined different tools used to assess either quality of life or 
palliation of lung cancer-related symptoms by conducting a literature review of quality of 
life measurement in cancer patients receiving palliative radiotherapy for symptomatic 
lung cancer. The most common tool used was EORTC QLQ-C30. Fourteen of 43 studies 
(32%) identified out of which eight used EORTC QLQ-C13—a supplemental version of 
a lung cancer-specific questionnaire. The questionnaire consisted of items concerning 
lung cancer symptoms and the side effects of conventional treatments used for lung 
cancer (Salvo et al., 2009). Some of the quality of life domains considered was dyspnea, 
diarrhea, and loss of appetite, among others (Salvo et al., 2009). FACT-L, which is 
analogous to EORTC QLQ-LC13 and includes additional questions that relate 
specifically to quality of life in patients with lung cancer, was used in two studies. Spitzer 
quality of life index, a third validated quality of life tool and covers 5 dimensions of 
quality of life was used. The 5 dimensions covered were activity, daily living, and health, 




to determine quality of life was used in three trials, and nineteen trials attempted to 
evaluate symptom palliation using a study-designed questionnaire.  
The authors found out that in a total of twenty identified trials that were 
considered for palliative radiotherapy for lung cancer and evaluation of quality of life, 11 
used a tool that was specific to patients with lung cancer, while the remaining nine used 
overall quality of life questionnaires for cancer patients or a study-designed questionnaire 
(Salvo et al., 2009). Also, in 31 identified studies, the level of symptom palliation, one 
aspect that contributes to a quality of life measure was assessed, where the authors 
concluded that more trials should use a validated lung-specific tool to allow for 
comparisons between trials which will in turn increase the internal validity of individual 
studies (Salvo et al., 2009). The authors therefore, recommended that lung-specific 
validated tools that would be beneficial for the measurement of quality of life in trials 
evaluating palliative thoracic radiotherapy should be FACT-L and the EORTC QLQ-
LC13 (Salvo et al., 2009). Nevertheless, FACT-L was not chosen for the proposed study 
because it goes well beyond the scope as it is some broader instrument measuring social 
and emotional domains.  
Another study involving HRQL assessment in lung cancer was conducted using 
lung cancer tools EORTC QLQ-C-30 version 3.0 and C-13 at baseline and at day 1 of 2, 
4, and 6, and after 6, and 8 weekly thereafter until disease progression (Nowak et al., 
2004). In the same way, Earle (2004), studied and compared five quality of life 
instruments (FACT-G, FACT-L, EORTC QLQ-C30, EORTC QLQ-LC 13, and LCSS) 
noting merits and demerits and concluded that the use of these instrument in measuring 




study assesses HRQL in lung cancer treatment, it was imperative that it followed the 
timeline documented in literature. For example, a study involving HRQL assessment in 
lung cancer was conducted using lung cancer tools EORTC QLQ-C-30 version 3.0 and 
C-13 at baseline and at day 1 of 2, 4, and 6, and after 6, and 8 weekly thereafter until 
disease progression (Nowak et al., 2004). Similarly, Balduyck et al. (2007) in their study 
on quality of life evolution after lung cancer surgery predicted “changes in 1, 3, 6, and 12 
months after the surgery” (p. 429). Other studies have been done using these same 
instruments and span over a period of 1-4 months (Lemonnier et al., 2014; Nowak et al., 
2004; Tse et al., 2005). 
Literature on Research Design and Conceptual Framework 
This section reviewed studies that used analysis derived from comparative design 
and the conceptual model. Holland et al. (2009) listed different interventions that have 
been used to help older adult patients with lung cancer. The older lung cancer patients 
exhibited cognitive coping skills by showing improvement in processing difficult events. 
Interventions that focused on anxiety reduction (including loss of appetite) were provided 
as helpful tools to assist processing of painful past and present events. These 
interventions were effective. The article reported, in two studies, a psychoeducational 
intervention delivered via a telephone showed efficacy of interpersonal 
psychoeducational intervention in reducing distress in older women with breast and lung 
cancer (Holland et al., 2009). Similarly, several psychoeducational techniques were tested 
in samples of cancer patients with older adult patients (Holland et al., 2009). In addition, 
Holland et al. (2009) reported that after reviewing men who are 65 years old with cancer 




quality of life and helped patients find benefits from their cancer experience. The 
preceding evidence from research helped to buttress the fact that psychoeducational 
intervention aids older adult cancer patients improve disease regimen if they are engaged 
in quality of life activities. The authors therefore concluded that a review of literature 
supports that psychoeducational interventions assisted in improving quality of life in 
older adult lung cancer patients (Holland et al., 2009). Additionally, the authors stated 
one cannot manipulate treatment or therapy of lung cancer patients, and therefore, 
postulated that an observational study is best rather than an experimental study in which 
the criterion is used to manipulate the independent variable (Holland et al., 2009).  
A review of randomized controlled trial data showed that early palliative care 
improved survival, quality of life, and depressive symptoms in those with NSCLC 
compared to standard care (Davis, 2012). However, symptom burden of lung cancer was 
great and at least 80% of the patients experienced fatigue, 65% suffered loss of appetite, 
77% exhibited cough, 73% exhibited dyspnea (from both local symptoms and weight 
loss), 57% had chest pain, and 17% had hemoptysis (Davis, 2012). In addition, symptom 
frequency and severity could be worse in individuals who survived 3 months or less 
(Davis, 2012). Therefore, early palliative care improves quality of life and decision-
making in patients with advanced lung cancer and may improve survival (Davis, 2012). 
The ability to evaluate and apply evidence-based guidelines into daily practice has 
become an important aspect of medical care. Integrating evidence-based guidelines in 
lung cancer treatment involves the development of theory and a method of action from a 
systematic review of current evidence (Pearson, Field, & Jordan, 2007). Given the ability 




from this study will be used to complement the existing evidence on treatment 
effectiveness. 
Summary and Transition 
Treatment of older adult lung cancer patients is historically understudied. Because 
most lung cancer clinical trials are linked to younger patients, older adult lung cancer 
patients have been under-represented and, as such, treatment recommendations based on 
extant data are inadequate in routine clinical practice with older adults. However, to 
thoroughly characterize the scope of the under-representation that older adult lung cancer 
patients face and to obtain data regarding outcomes, it should be a consensus approach. A 
quality of life assessment may be very helpful and useful for older adult lung cancer 
patients by improving rapport or better communication between the patient and the 
provider. This relationship could improve recommendations for a wider application of 
properly selected treatments.  
The two previous chapters detailed the increased incidence in lung cancer among 
older adults. While modern medicine and technology has increased the number of 
treatment options, there is a paucity of research related to the impact these options have 
on HRQL in older adults with lung cancer. Patients undergoing any treatment need to 
understand the impact it will have on their quality of life. Ethically, in making their 
decision, it is the patients’ right to be informed of all sequelae of any treatment or no 
treatment. Chapter 3 will provide the description of the study design, participant' 
procedures, and data collection, as well as data analysis, and protection of human 




Chapter 3: Research Method 
Introduction 
The purpose of this study was to assess the effect of lung cancer treatment 
modality on HRQL among older adults. I carried out an ancillary comparative survey to 
determine whether there were differences in physical functioning, symptom burden, and 
overall quality of life experience between surgery and tumor ablation lung cancer 
treatment modalities. This chapter begins with an overview of the study research design 
and the rationale for why this research design and approach were selected. The rest of the 
chapter includes discussion of the setting where the study took place, participant 
recruitment, sample characteristics and sample size, and materials and instrumentation. 
The logistics entailed in obtaining and scoring data for the comparative survey of HRQL 
is described in the data collection process. I describe the operational measures of the 
independent and dependent variables in the statistical analysis section as well as 
statistical tests performed for hypothesis-testing, followed by ethical considerations. 
Research Design and Approach 
The research design of this study was a quantitative, comparative survey based on 
treatment modality and assessment with repeated measures. In a comparative study, the 
critical issue is to determine whether the participating groups differ with regards to the 
dependent variable (HRQL dimensions) without manipulating the independent variable 
(treatment). This rationale forms the basis of the research design of the study. 
My approach was to carry out an ancillary study to an existing randomized 
clinical trial of lung cancer in older adults. The participants were assigned to one of the 




randomization to either group does not present additional ethical concerns within the 
scope of this research. The ancillary component to the clinical trial consisted of a 
comparative survey research design. According to Mills, van de Bunt, and de Bruijn 
(2006), the comparative nature of a study constrains the researcher to observe the effects 
of the independent variable (treatment) on a dependent variable (outcome), without direct 
intervention or manipulation of the former.  
I considered other methods of quantitative inquiry but determined that they would 
less effective in providing the insight relative to a randomized clinical trial with 
comparative survey follow-up. I also considered a multiple case study; however, this 
design is not as powerful as the comparative survey. One of the advantages of the 
randomized clinical trial design is the ability to control for immutable characteristics (e.g. 
age, ethnicity, or place of birth) which are unlikely to have a direct effect on the outcome 
when participants are grouped at random (Stevens, 2009). The quantitative approach is 
the preferred design for a comparative study with repeated-measures because the interval 
and ratio scales are conducive to parametric statistics.  
 The nature of the HRQL scale I selected is continuous and this level of 
measurement is frequently used because they are numerical and are often used in 
quantitative studies. The quantitative method is more useful in testing effects than the 
qualitative method. The quantitative method maximizes similarities and differences on 
the information gathered (Creswell, 2003). The goal of a quantitative study is to 
determine, with a degree of statistical certainty, whether an effect is likely to exist 





 I used generalized estimating equations (GEE) to model self-reported quality of 
life measures over time between ablation and surgery conditions (Hanley et al., 2003). 
GEE provides a semiparametric approach to longitudinal analysis of categorical response 
and can also be used with continuous measurements. Instead of attempting to model the 
within-subject covariance structure, the GEE procedure treats the covariance structure as 
a nuisance and simply models the mean response. Count data rarely fit the restrictive 
assumptions of the Poisson distribution and violation of these assumptions frequently 
result in overdispersion (Hammami, Garcia & Nuel, 2013); data that are overdispersed 
have a variance that is larger than the mean. Therefore, to account for the overdispersion, 
I assumed a negative binomial distribution because patient scores were nested within 
patients. When the data have a heterogeneous compound symmetry covariance structure, 
the sandwich estimator is used to correct for model misspecification (Guillaume, Hua, 
Thompson, Waldorp & Nichols, 2014). For example, in my study the sandwich estimator 
accounts for the repeated measures correlation from baseline to 1-month and 3-month 
follow-up.  
Changes in quality of life dimensions were compared between treatment 
modalities' negative binomial distribution with one three-level within-subjects factor (i.e., 
time: baseline, 1 month, and 3 month), and one two-level between-subjects factor (i.e., 
modality: surgery versus tumor ablation). The within-subject’s changes from baseline 
were compared between each pair of modalities at each follow-up time using six 
orthogonal contrasts. The comparison of the repeated measures was between baseline and 
1-month, baseline and 3-months and between baseline and 3-months since the emphasis 




between 1-month and 3-months, thus analysis was made between those two times. All 
statistical analyses and modeling were conducted using SAS© Software 9.4 with PROC 
GLIMMIX procedure.  
 I planned repeated measures of HRQL and these introduced an effect of repeated 
testing upon statistical analyses. To correct for the effect of repeated testing, orthogonal 
contrasts are computed within and between conditions using the Holm-Bonferroni 
correction. Orthogonal contrasts for analysis of variance are independent linear 
comparisons between the groups of a factor with at least three fixed levels, such as the 
three-time periods and two treatment groups in my study.  
The Holm-Bonferroni correction represents an adjustment made to p-values when 
several repetitive statistical tests are performed simultaneously on a single data set 
(Stevens, 2009). The Holm-Bonferroni correction is based on the idea that if an 
experimenter is testing n dependent or independent hypotheses on a set of data, the 
probability of type I error is offset by testing each hypothesis at a statistical significance 
level 1/n times what it would be if only one hypothesis were tested (Napierala, 2012). As 
suggested by Napierala (2012), to perform a Holm-Bonferroni correction, the critical p 
value (α) is divided by the number of comparisons being made. For example, if 10 
hypotheses are tested, the new critical p-value would be α/10. The statistical outcomes of 
the study are then determined based on this modified p-value (Napierala, 2012). The p-
value used in this study was .05 and the number of hypotheses tested on the data set was 
three, hence, the chance of obtaining a false-positive result was 15% percent. The 
Bonferroni correction required an adjustment to the p-value from .05 to .016 to neutralize 




priori at the .05 level and all interval estimates were calculated for 95% confidence. 
Thus, the effect assessed in each hypothesis tested was considered significant only if the 
p-value was below .016. 
Nowak et al. (2004) and Win et al. (2005) suggested follow-up for 3-months after 
treatment to provide adequate time to compare differences from baseline and 1-month 
and 3-months. In addition, Hollen et al., (1999) suggested that the most important 
response and toxicity assessment is reached within 90 days (p. 141). Balduyck et al. 
(2007) and Cella et al. (1995) concurred that observations for studies of this nature have a 
duration between baseline and 1, 2, 3, 6-12 months. Balduyck et al. (2007) used a 
comparative design for their study on quality of life evolution after lung cancer surgery 
and predicted changes at 1, 3, 6, and 12 months after the surgery. Similarly, Cella et al. 
(1995) reported a 2-month follow-up time for their study on reliability and validity test 
using FACT-L (p. 205). Other studies I reviewed spanned over a period of 1 to 4 months 
(Nowark et al. 2004; Tse et al. 2005). Considering the average timeframe, I chose a data 
collection period of baseline, 1-, and 3-months. 
Setting and Sample 
The setting of the study was a private hospital with a National Cancer Institute-
designated cancer center in the Northeast part of the country. Participants were volunteers 
who underwent stand-alone tumor ablation, or stand-alone surgery procedures for small-
cell lung cancer. Inclusion criteria were 65 years and older, previously randomized to 
undergo surgery or tumor ablation as the treatment modality, diagnosed with lung cancer 
stages I, II, and III, and agreement to participate in the 3-month HRQL survey. 




procedures and policies of the hospital, participants meeting the inclusion criteria 
described above were selected from diagnosed lung cancer patients who visit the cancer 
center and had been randomized to a treatment group. These patients were referred to 
participate in the ancillary survey research study by oncologist, diagnostic imaging 
researcher/principal investigator, and a thoracic surgeon at the cancer center.  
The oncologists arranged for the patients to be contacted ahead of time using the 
established hospital’s IRB rules and regulations affecting research (Appendix A). At the 
doctor’s visit, I was present to discuss the study with the participants (as discussed it with 
the oncologist beforehand) and if they had agreed, I contacted them using the preferred 
method of contact, which they had selected either by phone or mail. Although the 
participants were referred to me by the principal investigator and the oncologist, it was 
their choice to provide their contact information during the first meeting to me.  
Written information introducing the study and an informed consent form were 
disseminated via individual patients’ chosen mailing addresses. The informed consent 
form included brief background information on the study, the procedures for 
participation, a discussion of confidentiality, the voluntary nature of the study, and other 
ethical concerns. The participants were asked to arrive 30 minutes early for their 
oncology appointments or be available 30 minutes after their appointment, depending 
upon which was more convenient for them. The extra time allowed for the visit gave 
them an opportunity to ask questions on the informed consent and complete the LCSS 
and demographic surveys. 
The cancer center examines between 100 and 120 adult cancer patients per day or 




provided by tally from an oncologist of the cancer center (A. Birnbaum, personal 
communication, March 10, 2015). About 250-300 (50%) of these patients are 65 years 
and older, of which 75-105 (30%-35%) have non-small cell lung cancer. Out of a 
maximum number of 105 older adult lung cancer patients who are seen at the oncology 
clinic on a weekly basis, it was assumed that about 94 participants could be approached 
for the study each week. Allowing a refusal rate for the randomized study to be about 
10% (RIH Cancer Center), 80 patients were recruited for the ancillary survey. 
 Effect size was based on the means and standard deviations from previously 
published literature, where the assumption was that with a “within-subjects” correlation 
of 0.5, power would exceed 80% to detect a difference of 0.7 standard deviations 
between groups. I used one between-subjects factor with two levels (i.e., treatment) and 
one within-subjects factor with three levels (i.e., time point) to determine the differences 
between the group means, after Holm-Bonferroni adjustment (Cleophas et al., 2009; 
Gravetter & Wallnau, 2004).  
Based on previous studies with medium effect sizes (Damm et al. 2013; Davis, 
2012; Hoffmann et al. 2014; Kasymjanova, Grossman, Tran, Jagoe, Cohen, Pepe et al. 
2013), I expected to find a medium effect size as well. To determine the sample size, I 
calculated the power analysis for ANOVA designs as discussed in Cohen (1988) and 
Stevens (2009). Using the medium effect size of 0.40 (f squared), significance level (a) of 
0.05, and power of 0.80 yielded population size of 66 (N = 66) for the two therapies 
(Stevens, 2009). To confirm the results, the University of Colorado, Colorado Springs 
sample size and effect size calculators were used. Becker (2014), based his calculations 




significance level of 0.05) and calculated a sample size of 66. Using another medium 
effect size of 0.30 but same power and significance level produced a sample size of 62 
(Becker, 2014). Based on the above calculated results, I estimated for my study a sample 
size a total of about 60-70 participants for both modalities, with a minimum of 30 
participants per modality. However, the sample recruited my study with complete 
administration of all three forms was 70 participants for the two therapies (35 participants 
for each modality).  
Instrumentation and Materials 
Two instruments were used to collect data for this study: a brief demographic 
survey and the LCSS analogue scale. Both instruments were administered to older adult 
lung cancer patients who volunteered to participate in the study and met the inclusion 
criteria prior to beginning one of the two selected treatment options. The survey 
administration prior to treatment represented the baseline measurement. At 1, and 3-
month interval post-treatment had commenced, the two instruments were administered 
again. Each of the instruments is described below.  
Demographic Survey. I obtained basic information regarding the type of 
treatment selected, age, gender, education, race/ethnicity, marital status, and income 
above or below $75,000. This demographic data collection tool is found in Appendix B. 
Demographic data collected was used to determine the demographic composition of the 
sample, which was matched to data at the baseline, 1-month and 3-month follow-up 
responses. Participants were not required to provide demographic information at either of 
the two follow up assessments. Using the data that participants consented to provide on 




extensive permission to access. These data were used as controls prior to analysis. In 
doing so, I compared the two groups based on their demographic features to determine 
how comparable they are. 
Lung Cancer Symptom Scale. The Lung Cancer Symptom Scale (LCSS) was 
first developed in 1995; the primary developers were Patricia Hollen, Richard J. Gralla, 
and Mark G. Kris (Hollen et al. 1995). LCSS is a “quality of life instrument used to 
evaluate physical and functional domains of individuals diagnosed with lung cancer at a 
specific site devoid of toxicity of treatment" (Hollen et al. 2005; Earle, 2004). The patient 
scale used originally consisted of nine items: six measuring major symptoms for lung 
cancer— “appetite loss, fatigue, cough, dyspnea, hemotypsis, pain, and three summation 
items related to total symptomatic distress, activity status and overall quality of life” 
(Hollen et al., 2005; Hollen et al. 1995, p. 57). The idea behind the development of the 
scale was to provide a practical quality of life measure that will reduce patient and staff 
burden in serial measurement of quality of life during a clinical trial (Hollen et al. 1995). 
The scale captures the dimensions most likely to be influenced by therapeutic 
interventions and evaluates other dimensions globally (Hollen et al. 1995).  
The participant assigns an individual score on each item on the scale by placing a 
line across an analogue 100mm line that ranges from zero (better status) to 100 (worst 
status) (Appendix D) (Hollen et al. 1995). The LCSS has been tested in over 1000 
patients with lung cancer in many international studies (Browning et al. 2009; Hollen et 
al. 1993; 1995). The LCSS has undergone comprehensive testing for psychometric 
properties of feasibility, reliability (coefficient alpha for internal consistency, test-retest 




approach, relationship testing, multitrait-multimethod approach, and criterion-related 
validity) (Hollen et al., 2005). Good sensitivity to all levels of the Karnofsky scale is 
reported as part of the construct validity of the LCSS (Hollen et al., 1995). Scoring is 
done by measuring equal lengths of line marked on analogue cards and an aggregate 
score of all nine items is used for the total score (Hollen et al., 1995).  
 The LCSS scoring is computed by adding the scores from 0-100 from the 
responses received from the participants of all eight patient items to determine the total 
score and then the average (mean). The single quality of life is evaluated based on 
responses to item nine (item eight is not evaluated), then the average symptom burden 
index is obtained based on a mean of items one through six (Hollen et al., 1995). This 
scoring procedure results in one continuous quality of life score, a continuous average 
symptom burden index, and a total score, resulting in a total of three scores (Hollen et al., 






Description of Demographic and HRQL Operational Measures 




Physical Functioning   
   Shortness of Breath 
   Appetite 
   Cough 
   Fatigue 
   Hemoptysis 
 
   Pain 
Amount of SOB 
How good is appetite 
Cough frequency 
Amount of fatigue 
Amount of blood in 
cough 















    
Overall Quality of 
Life Experience 
Overall quality of 








Mean of 6 Domain 
items 
 
0—600 ÷ 6 Continuous 










6=Hispanic or Latino 
7=Preferred not to 
answer 
Nominal 
Income Total income in past 
year 
0=≤$75, 000  
1=>$75, 000 
Ordinal 
Education Level of education 1=Not a High School 
graduate or equivalent 
2=High School graduate 










 The data collection followed a sequence of steps to recruit, inform participants, 
and collect data. The IRB approval was received from both the private hospital and 
Walden University to conduct the study (Appendix A). The principal investigator of the 
lung cancer clinical trial at the private hospital served as the onsite principal investigator 
of the ancillary protocol on HRQL that used to collect data for this dissertation study. At 
the private hospital, I served as co-investigator of the ancillary study. The hospital IRB 
had the primary responsibility for overseeing the data collection of the comparative 
survey. Walden had secondary responsibility as the institution supervising student 
research, by coming into agreement with the hospital to protect the data rights to carry 
out this dissertation study. The dissertation proposal was submitted to Walden University 
IRB as an ancillary study added onto an existing randomized clinical trial. The ancillary 
component consisted of a comparative survey research design intended to assess 
additional symptomatic changes not examined in the existing randomized clinical trial. 
Baseline Survey. I met with the research oncologists at the cancer center of the 
hospital to explain the study, reviewed necessary documents, as well as to elicit support 
for referral of patients who met the inclusion criteria. During the initial meeting, 
participants who agreed to volunteer in the study were asked to provide contact 
information using their preferred method, either by phone or mailing address. This 
contact information was only used to send information regarding the study and to arrange 
a time during their hospital visit to complete the demographic and LCSS forms. I spent 




cycled through their appointment as well as being processed for initial treatment. During 
this time, I obtained the consent from the participant/patient in the presence of the doctor.  
I then contacted the patients referred by using their preferred mailing method 
explaining the nature of the study and providing a contact telephone number. In the letter, 
I asked the referred patients to contact me through a phone call or e-mail to arrange for 
them to arrive at least a half hour early to their next oncology visit or half an hour after 
their doctor’s visit, whichever one was convenient for them. I explained and discussed 
the ancillary study survey and the separate consent form to them. Each participant was 
asked if they were willing to participate. All participants who consented were contacted 
promptly to ensure speedy screening. All these instructions were explained at the initial 
meeting before participation starts. Once they agreed to participate in the study and select 
a convenient timeframe, they were asked to sign a consent form and complete the survey. 
The discussion took place in a private consultation room in the cancer center. 
After diagnosis, the patient is contacted by the cancer center for follow up 
computed tomography (CT) scan of the chest. At the consultation, the patient and the 
doctor discussed the different treatment modalities available to include the advantages 
and disadvantages associated with each treatment. The consultation takes place to enable 
the patient to decide which modality he/she would opt for. After this consultation, the 
patient was scheduled for the procedure depending on availability of the hospital's 
schedule which normally takes anywhere from three weeks to two months. Patients went 
through the necessary preparation for the chosen modality to include mental preparation, 
availability, and procedures. On the day of the procedure, the patients arrive about 1-2 




sure that the patient followed the rudiments of the procedure. The patient awaits in a 
recovery room to talk to the oncologist to get signatures, consent forms, or anesthesia. 
After the consultation with the physician assistant, the patient is admitted to the 
procedure room and waits anywhere from 1-3 hours. During this 1 to 3-hour period, the 
patient's heart rate, and blood pressure, are monitored and "time out" (procedures are 
conducted. Time out refers to all personnel involved in the procedure consulting each 
other to make sure all paperwork and other pertinent information about the patient are 
concluded. During the 1 to 2- hour time out period, I met with the patient to go through 
the baseline survey (this had been communicated to the patient during the earlier doctor's 
visit). 
Follow-up Surveys. Participants were scheduled to complete the 1-month and 3-
months follow-up surveys at the same time when they had appointments for follow-up of 
their cancer treatment. In case follow-up surveys were not completed at the 1- or 3-month 
timeframe, the lung cancer symptom scale questionnaire was mailed to the participants’ 
home asking them to complete and mail back to the cancer center using enclosed self-
addressed stamped envelopes. The 1- and 3-month periods are a standard follow-up time 
at the hospital after surgery and ablation (personal communication with D. Dupuy, tumor 
ablation doctor, researcher, and principal investigator; T Ng, researcher and thoracic 
surgeon as well as A. Birnbaum, oncologist, April 15, 2015). 
In addition to prior communication, there was discussion with the above-named 
physicians to confer the participants’ follow-up schedules (with permission from the 
participants) to contact them for the follow-up survey. The surveys were administered 




comparative survey was used to link all completed surveys and clinical data on the 
participants (clinical trial participant and treatment modality). The ancillary study data 
were not made available to anyone outside the ancillary study team. I input the data into a 
computer. Hard copy questionnaires were kept in a locked file in the investigator’s office 
and electronic data files password protected. The hard copy questionnaires will be 
destroyed after five years.  
A follow-up phone call was used to gather information from participants that were 
hospitalized; participants that were too ill or did not wish to respond were excluded from 
the survey and another participant was recruited. Early evaluation helped to alleviate or 
minimize any refusals to participate in the next phase of the study. This also helped me to 
ascertain if the participants were continuing with original treatment, had adopted 
combination treatment or any other treatment option, and to assess their quality of life 
changes as enumerated in the questionnaires. Participants who adopted any combination 
of therapy were excluded from the study and new participants were sought via the 
research oncologist. 
Administration of Survey. Data were collected through two sets of survey 
questions at baseline, including both the LCSS and a brief demographic questionnaire. 
Following this baseline survey, participants were not required to provide demographic 
information at follow-ups. The demographic information was used to describe baseline 
treatment group differences.  
The LCSS tool is meant to elucidate participant physical and functional well-
being while undergoing lung cancer treatment. The literature suggests that the majority of 




a change in at least one of the HRQL domains under consideration as described in 
chapter 2. The LCSS instrument was selected because the symptoms included are parallel 
to the symptoms experienced by patients during lung cancer treatment. These symptoms 
are the participants’ pain, shortness of breath, appetite, cough, hemoptysis, and fatigue as 
well as symptomatic distress and overall quality of life for the lung cancer experience. 
The LCSS tool helped evaluate the participants’ experience across the quality of life 
dimensions after going through the procedures during the two treatment modalities. 
Permission was granted to use the LCSS scale by the authors (see Appendices D and E). 
In addition, IRB procedures from the hospital were obtained to conduct ancillary study 
and permission to do this study under a qualified principal investigator (see Appendix A). 
The LCSS instrument uses a scale consisting of continuous numbers ranging from 
0-100, with zero corresponding to the lowest rating—best status and 100 representing the 
highest rating—worst status (Hollen et al., 1995 p. 3; Appendix F). This scoring system 
was used to score the three dimensions (Appendix E). As per the original methodology, 
participants were asked to indicate their rating of symptoms on a set of cards provided. 
They were asked to mark a small line to indicate the severity of each symptom, as well as 
the overall quality of life. Each item was scored to the length of the line marked by the 
participant equivalent from 0 to 100 on the line in millimeters. A marked ruler was used 
to measure the exact value indicated as the measure for the variable (Appendix F). To 
create aggregate scores for a total score, average symptom burden index, and quality of 
life measure, means were calculated using the following procedures: A mean of all eight 




for the average symptom burden index, and raw score was examined for overall quality 
of life for the lung experience (see Appendix E). 
Statistical Analysis 
The characteristics of the participants included bivariate analysis to compare 
demographic differences among the two treatment groups on age, gender, ethnicity, 
marital status, and income. Demographics and clinical characteristics were compared 
between two treatment groups involving quality of life dimensions using descriptive 
statistics such as means, medians, percentages and p-values.  
Means from all eight items were computed to develop a single total score. 
Average symptom burden index of the six major lung cancer symptoms was obtained as 
the average of items one through six. An overall quality of life score was obtained. This 
allowed me to compare the means responding to the various treatments and 
corresponding quality of life domains (Rudestam and Newton, 2001). 
 The study sought to answer three research questions with three hypotheses based 
on comparisons of the effect of treatment on quality of life measures. Self-reported 
quality of life measures was modeled over time between ablation and surgery conditions 
using generalized estimating equations (GEE) (Hanley et al., 2003). A negative binomial 
distribution was assumed (for overdispersion), where patient scores were nested within 
patients, assuming a heterogeneous compound symmetry covariance structure with 
sandwich estimator to correct for model misspecification. Planned comparisons 
(Orthogonal contrasts) within and between conditions were examined using Holm-




and all interval estimates were calculated for 95% confidence. All statistical analyses and 
modeling were conducted using SAS Software 9.4 with PROC GLIMMIX.  
Research Question 1: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H01): There are no significant differences in LCSS total scores 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Alternative Hypothesis (Ha1): There are significant differences in LCSS total 
scores between the two lung cancer therapies (surgery or tumor ablation) measured at1-
month and at 3-months period. 
Statistical Plan 1: Independent variables: Treatment modalities and time periods; 
dependent variable: Physical functioning (LCSS total score); statistical test: Generalized 
Estimating Equation; criteria to reject Null: p < .016.  
Research Question 2: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H02): There are no significant differences in average symptom 
burden index scores between the two lung cancer therapies (surgery or tumor ablation) 




Alternative Hypothesis (Ha2): There are significant differences in average 
symptom burden index scores between the two lung cancer therapies (surgery or tumor 
ablation) measured at 1-month and at 3-months period. 
Statistical Plan 2: Independent variables: Treatment modalities and time periods; 
dependent variable: Average symptom burden index score; statistical test: Generalized 
Estimating Equation; criteria to reject Null: p < .016.  
Research Question 3: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H03): There are no significant differences in quality of life 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Alternative Hypothesis (Ha3): There are significant differences in quality of life 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Statistical Plan 3: Independent variables: Treatment modalities and time periods; 
dependent variable: Overall quality of life for the lung cancer experience score; statistical 






Protection of Human Participants 
The participants in this study were patients who are 65 years and older who 
underwent surgery and tumor ablation for lung cancer as part of their enrollment in a 
randomized clinical trial, and who spoke English language. Informed consent for this 
ancillary comparative survey study on HRQL was obtained from each subject prior to 
commencement of the cancer treatment. Each participant was informed that participation 
is separate from enrollment in the clinical trial and was entirely voluntary and regardless 
of their participation, it would not impact their treatment at the private hospital’s 
oncology department, that there were minimal risks associated with the study, and that 
there was no compensation for their participation.  
The Hospital where the clinical trial took place oversaw the data collection of the 
ancillary study and served as the primary supervising institution. I served as the Co-
investigator of record and its IRB approved the collection of data for the study. I 
collected the ancillary study data as part of my role at the hospital. Therefore, Walden 
and the Hospital had a data use agreement to make sure that the data were clearly mine to 
analyze as part of this dissertation study.  
The participants were informed that they could decline to be part of the study at 
any time or refuse to answer any questions without penalty to treatment. Patients were 
informed that the sole benefits of the study will be to help health care professionals 
provide better care to future patients’ treatment for lung cancer. Any information they 
provide would be strictly confidential and all documents pertaining to this study would be 
assigned subject numbers to be able to match the records of the same patient. No names 




I was the only person who had access to the information or the documents. All 
information was reported in aggregate and no individual responses were shared. 
Precautions were taken to ensure the validity and reliability of the findings of the study. If 
participants needed any assistance to cope with the findings, they would be informed of 
resources for follow-up support.  
Summary and Transition 
The approach to the study was a quantitative comparative survey, carried out as 
an ancillary study to an ongoing randomized clinical trial of non-small cell lung cancer. 
Newly diagnosed older adults who underwent surgery or tumor ablation treatment 
modalities for their lung cancer and who had already consented to participate in the 
clinical trial were asked to volunteer in the ancillary study. Participants were asked to 
complete a survey including demographic information and an 8-item symptom scale. 
Baseline data were collected in person by the researcher and follow-up at 1- month and 3-
months post treatment. Surveys were completed during appointments for follow-up of 
their cancer treatment or by mailing the lung cancer symptom scale questionnaire to the 
participants’ home. The next chapter, Chapter 4, will discuss the results following 




Chapter 4: Results 
Introduction 
The purpose of this study is to assess the effect of two lung cancer treatment 
modalities on HRQL physical functioning, symptomatic distress and overall quality of 
life experience among older adults. I used a quantitative, ancillary study approach that 
consisted of a comparative survey based on treatment modality and examined baseline 
and two follow-up time points. A comparative study helps to find already-existing groups 
categorized by an independent variable (treatment) that differ in dependent variables 
(HRQL dimensions). The data collection spanned over 5 months. The results of Chapter 
4 are divided into four sections, including: (a) sample characteristics, (b) research 
question and hypotheses testing (c) statistical analysis, and (d) summary and transition.  
Participant Recruitment and Attrition 
The study participants were patients enrolled in a randomized clinical trial for the 
treatment of non-small-cell lung cancer using either tumor ablation or surgery. The 
patients were treated at a cancer center in a hospital in the Northeastern part of the United 
States. The inclusion criteria for the comparative survey was that they be 65 years and 
older and spoke English. Eighty (n = 80) participants signed the consent form to take part 
in the comparative survey. Out of the 80 patients who volunteered for the ancillary study, 
42 were randomized in the clinical trial to the tumor ablation group and 38 to the surgery 
group. Two tumor ablation patients and one surgery patient (out of the 80 who consented) 
changed their minds and withdrew before providing baseline information. Out of the 38 
surgery patients, one withdrew, and another died before completing the baseline survey, 




group with complete data was 35 (n = 35). The tumor ablation group was reduced from 
42 to 35 because two patients withdrew and two died before baseline, and three did not 
meet the study inclusion criteria (two patients had stage IV lung cancer and one had 
ablation of the esophagus not lung). While the two treatment groups in the ancillary study 
ended up with equal numbers, the initial participation and loss to follow up had different 
pathways.  
Characteristics of Sample 
Newly diagnosed patients enrolled in a randomized clinical trial of lung cancer 
were recruited to participate in the comparative survey to test the effect of two treatments 
on repeated measures of HRQL. The ancillary study sample consisted of 70 volunteers 
(35 in each treatment) that met the inclusion criteria and completed the three surveys. 
Although randomization in a clinical trial ensures equal groups at baseline, the 70 
participants for the comparative survey were self-selected and not randomized. At 
baseline there were significant differences between the two treatment groups in average 
symptomatic distress (p = .0070) but not physical functioning (p = .0240; Bonferroni 
adjusted p < .016), and overall quality of life experience scores (p = .1893). 
The demographic characteristics of the baseline participants by treatment 
modality are shown in Table 5. The two groups were only statistically significant in age 
(p = .0049) with mean age 65 years for surgery patients and 66 for tumor ablation. Two-
thirds (65.8%) of surgery patients were female, over half (55.3%) were married, and over 
two-thirds (68.4%) earned less than $75,000 annually. Two-thirds (65.4%) of tumor 
ablation patients had high school or less education, one-third (34.6%) were widowed and 





Distribution of Demographic Characteristics by Treatment Domain 
Demographic Domains Surgery 
(%) 
N = 35 
Tumor 
Ablation (%) 
N = 35 
p-value 
Age 
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    Not a High School graduate 
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     Some College 
     College Graduate 










  7.7 
23.1 
  3.8 
.1574 
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94.7 
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     >$75,000 



















Three research questions and three hypotheses were tested using generalized 
estimating equations (GEE; Hanley et al., 2003). GEE is a multilevel regression 
technique that adjusts standard errors to account for correlated data, such as the 
correlation of repeated measurements in a longitudinal study (Huh, Flaherty, and Simoni, 
2012). Huh et al. first described the GEE statistical test along with its assumptions and 
steps taken to test these assumptions. In the GEE statistical analysis to test hypotheses, I 
present each research question and hypothesis with associated findings in sequential 
order. In addition, least mean squares estimates were computed and graphed for baseline, 
1-month, and 3-months for the LCSS total scores of the HRQL physical functioning 
symptoms, average symptom burden index scores as well as overall quality of life 
experience. The least mean squares estimates were elucidated to show the mean, the 
minimum and maximum means, the t-values and the adjusted p-values for the dependent 
variables listed and at the different time points. 
 Self-reported health-related quality of life was measured sequentially to determine 
the effect of time between tumor ablation and surgery treatment. The quality of life 
dependent variables has data that are right skewed and where the variance is much greater 
than the mean; these distributions lead to overdispersion and violate the assumption that 
the mean and variance are the same (Byers, Allore, Gill & Peduzzi, 2003). GEE analyses 
assume a negative binomial distribution for overdispersion, where patient scores are 
nested within patients. To correct for model misspecification, a heterogeneous compound 
symmetry (all response variables have the same variance) covariance structure with 




Regression parameters in GEE are first estimated through a generalized linear 
regression that initially ignores whether the data are longitudinal (Huh et al., 2012). A 
correlation structure is specified a priori and defines the hypothesized relationship 
between repeated observations on a subject (Huh et al., 2012). GEE approach is an 
extension of generalized linear models. GEE provides a semiparametric approach to 
longitudinal analysis of categorical responses; it can also be used for continuous 
measurements (Byers, Allore, Gill, & Peduzzi, 2003; Odueyungbo, Browne, Akhtar-
Danesh, & Thabane, 2008; Zhu & Lakkis, 2013). Instead of attempting to model the 
within-subject covariance structure, the core of GEE is designed to treat the covariance 
structure as a nuisance and simply model the mean response (Byers et al., 2003; 
Odueyungbo et al., 2008; Zhu et al., 2013). GEE involves specifying a model relating 
covariates to outcomes and a plausible correlation structure between responses at 
different time periods (Byers et al., 2003; Odueyungbo et al., 2008; Zhu et al., 2013).  
The key assumptions to do a GEE analysis include: (a) The responses: Y1, Y2, ..., 
Yn should be correlated or clustered, i.e., cases are NOT independent; (b) covariates can 
be the power terms or some other nonlinear transformations of the original independent 
variables, which can have interaction terms; (c) the homogeneity of variance does not 
need to be satisfied; (d) errors are correlated; (e) covariance specification are typically 
four or more correlation structures that are assumed a priori; and (f) it uses quasi-
likelihood estimation rather than maximum likelihood estimation (MLE) or ordinary least 
squares (OLS) to estimate the parameters, but at times these will coincide (Byers et al., 




To visualize the differences or changes in the types of variation I assumed that the 
raw scores received from the participants would be different in wide margins and that 
there would be no overlap between the two treatment modalities in terms of the outcome 
measure. The assumptions were tested using t-test, which is a test of two population 
means using statistical examination; a t-test is a test with two samples commonly used 
with small sample sizes, testing the difference between the samples when the variances of 
two normal distributions are not known (Trochim, 2006). To test the differences or 
changes in the types of variation in the variables, orthogonal contrasts were used. Within 
and between conditions where two treatment therapies were compared across three 
different time points were examined using Holm-Bonferroni corrections. Statistical 
significance was established a priori at the p < .05 level and all interval estimates were 
calculated for 95% confidence. All statistical analyses and modeling were conducted 
using SAS Software 9.4 with PROC GLIMMIX.  
The p-value was set at 0.05 and the number of hypotheses tested was three, hence, 
the chance of obtaining a false-positive result would be 25%, and the Holm-Bonferroni 
correction to adjust the p value for each hypothesis was .016 to neutralize the risk. The 
change in treatment differences over time were compared using results from baseline; 
between baseline and 1-month, and baseline and 3-months since there were no significant 
changes between 1-month and 3-months. The results were used to test whether the 
between-group variation exceeded the within-group variation.  
Research Question 1: Are there differences in health-related quality of life 




older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H01): There are no significant differences in LCSS total scores 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Alternative Hypothesis (Ha1): There are significant differences in LCSS total 
scores between the two lung cancer therapies (surgery or tumor ablation) measured at1-
month and at 3-months period. 
No significant differences in physical functioning were observed between surgery 
and tumor ablation patients at 1-month follow up (p =.7794) or at 3-month follow up (p 
=.2616). Thus, the null hypothesis is supported. The least mean squares estimate for 
baseline, 1-month, and 3-months for the LCSS total scores of the HRQL symptoms is 
presented in Table 6. Data include the mean, the minimum and maximum means, the t-
values and the adjusted p-values for the total scores of symptoms listed and at different 
time points. Following this table, the least squares means across the three-time periods 
were graphed in Figure 2. The means indicate that physical functioning was higher for 
tumor ablation compared to surgery at baseline, 1- and 3-months, while surgery was 
almost equal to tumor ablation only at 1-month post-treatment but lower than the mean of 
tumor ablation at baseline and 3-months. The scores of symptoms in the table above 
(Table 4) can range into the hundreds, yet the means are around 4 or 5. The scores are 
absolute values. The means were computed for statistical analysis using SAS. To obtain 
absolute values for the means, exponent of the mean needs to be calculated. For example, 




= 106.64 and that of tumor ablation (4.7205) is e(4.7205) = 112.22. Similar calculations 
were done at 3-months, where the mean values for surgery (4.4508) was e(4.4508) = 85.70 








Least Means Squares Estimates for Physical Functioning (LCSS Total Symptom Scores): Baseline, 1-Month, and 3-Months 
 




t- value Adjusted p 
Baseline Tumor Ablation 4.5920 4.3471 4.8369 37.12                - 
Baseline Surgery 3.9072 3.5325 4.2819 20.64                - 
1-Month Tumor Ablation 4.7205 4.4629 4.9782 36.27 - 
1-Month Surgery 4.6695 4.4180 4.9210 36.75 - 
3-Months Tumor Ablation 4.8367 4.6539 5.0195 52.37 - 
3-Months Surgery 4.4508 4.0847 4.8169 24.06 - 
 Tumor Ablation at baseline 0.6848 0.2372 1.1324 3.03       0.0240 
 Tumor Ablation at 1-month 0.0511 -0.3090 0.4111 0.28       0.7794 
 Tumor Ablation at 3-months 0.3859 -0.0234 0.7951 1.87       0.2616 
 Tumor Ablation 1-month-baseline 0.1285 -0.1503 0.4073 0.91       0.7268 
 Surgery 1-month-baseline 0.7623 0.4269 1.0976 4.50       0.0001 
 Delta Delta 1-month baseline -0.6338 -1.0699 -0.1976 -2.88       0.0332 
 Ablation 3-months-baseline 0.2447 -0.0025 0.4919 1.96       0.2616 
 Surgery 3-months-baseline 0.5436 0.1130 0.9743 2.50       0.0827 
 Delta Delta 3-months-baseline -0.2989 -0.7955 0.1976 -1.19       0.7071 



















Figure 2. Quality of life changes in physical functioning between the two treatments for 
LCSS total scores 
 
Research Question 2: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H02): There are no significant differences in average symptom 
burden index scores between the two lung cancer therapies (surgery or tumor ablation) 
measured at 1-month and at 3-months period. 
Treatment Ablation Surgery 
Least Squares Means for 
Interval*Treatment 











Alternative Hypothesis (Ha2): There are significant differences in average 
symptom burden index scores between the two lung cancer therapies (surgery or tumor 
ablation) measured at 1-month and at 3-months period. 
There were no significant differences between surgery and tumor ablation patients 
at 1-month follow up (p =.6395) or at 3-month follow up (p =.1345). Thus, the null 
hypothesis is supported. The least mean squares estimate for baseline, 1-month, and 3-
months for the average symptom burden index score of the HRQL symptoms is presented 
in Table 7. Data include the mean, the minimum and maximum means, the t-values and 
the adjusted p-values for the total scores of symptoms listed and at different time points. 
Following this table, the least squares means across the three-time periods were graphed 
in Figure 3. The means indicate that symptom burden was higher for tumor ablation 
compared to surgery at baseline, and 3-months, while the mean symptom burden for 







Least Means Squares Estimates for Average Symptom Burden Index Scores: Baseline, 1-Month, and 3-Months 
 




t- value Adjusted p 
Baseline Tumor Ablation 2.7060 2.4370 2.9750 19.91 - 
Baseline Surgery 1.8821 1.4801 2.2841 9.27 - 
1-Month Tumor Ablation 2.8764 2.5884 3.1643 19.77 - 
1-Month Surgery 2.9652 2.7254 3.2051 24.47 - 
3-Months Tumor Ablation 3.0458 2.8594 3.2323 32.33 - 
3-Months Surgery 2.5703 2.1738 2.9668 12.83 - 
 Tumor Ablation at Baseline 0.8239 0.1341 1.5137 3.37 0.0070 
 Tumor Ablation at1-month -0.0889 -0.6233 0.4455 -0.47 0.6395 
 Tumor Ablation at 3-months 0.4756 -0.1492 1.1004 2.15 0.1345 
 Tumor Ablation at 1-month-baseline 0.1703 -0.2068 0.5475 1.27 0.5501 
 Surgery at 1-month-baseline 1.0831 0.6154 1.5509 6.54 <.0001 
 Delta Delta 1-month-baseline -0.9128 -1.5137 -0.3119 -4.29 0.0003 
 Tumor Ablation at 3-months-baseline 0.3398 -0.0056 0.6852 2.78 0.0317 
 Surgery at 3-months-baseline 0.6882 0.0395 1.3369 2.99 0.0199 
 Delta Delta 3-months-baseline -0.3484 -1.0833 1.3369 -1.34 0.5501 
Alpha= 0.05; Delta-Delta 1-baseline=change/difference between 1-month and baseline; Delta-Delta 3-months-baseline=change/difference 

















Figure 3. Quality of life changes in symptom burden between the two treatments 
 
 
Research Question 3: Are there differences in health-related quality of life 
physical functioning, symptomatic distress, and overall quality of life experience among 
older adult lung cancer participants undergoing two-treatment modalities--surgery and 
tumor ablation--for small-cell lung cancer at 1-month and 3-months period? 
Null Hypothesis (H03): There are no significant differences in quality of life 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Treatment Ablation Surgery 













Alternative Hypothesis (Ha3): There are significant differences in quality of life 
between the two lung cancer therapies (surgery or tumor ablation) measured at 1-month 
and at 3-months period. 
Interaction effect refers to the relationship among three or more variables, and 
describes a situation in which the simultaneous influence of two variables on a third is 
not additive (Aguinis, Gottfredson and Culpepper, 2013)  
No significant differences were observed between surgery and tumor ablation 
patients at 1-month follow up (p =.9318) or at 3-month follow up (p =.5217). Thus, the 
null hypothesis is supported. Both ablation and surgery patients did not report significant 
changes after treatment at 1 month, (interaction effect, p=.1893) [Figure 4].  
The least mean squares estimate for baseline, 1-month, and 3-months for the 
overall quality of life experience of the HRQL symptoms is presented in Table 8. Data 
include the mean, the minimum and maximum means, the t-values and the adjusted p-
values for the total scores of symptoms listed and at different time points. Following this 
table, the least squares means across the three-time periods were graphed in Figure 4. The 
means indicate that overall quality of life experience was higher for tumor ablation 
compared to surgery at baseline, and 3-months, and the means were about the same for 








Least Means Squares Estimates for Overall Quality of Life Experience at 1-Month, and 3-Months 
 




t- value Adjusted p 
Baseline Tumor Ablation 2.9669 2.5562 3.3776 14.37 - 
Baseline Surgery 2.2418 1.7496 2.7340 9.06 - 
1-Month Tumor Ablation 3.2161 2.8869 3.5453 19.43 - 
1-Month Surgery 3.2367 2.8900 3.5834 18.57 - 
3-Months Tumor Ablation 3.2830 3.0152 3.5508 24.38 - 
3-Months Surgery 2.9096 2.5039 3.3153 14.26 - 
 Tumor Ablation at baseline 0.7251 0.08406 1.3662 2.25 0.1893 
 Tumor Ablation at 1-month -0.02062 -0.4987 0.4575 -0.09 0.9318 
 Tumor Ablation at 3-months 0.3734 -0.1128 0.8595  1.53 0.5217 
 Tumor Ablation at 1-month-baseline 0.2492 -0.1252 0.6236  1.32 0.5676 
 Surgery at 1-month-baseline 0.9949  0.4526 1.5373  3.65 0.0041 
 Delta Delta 1-baseline -0.7457 -1.4047 -0.08674 -2.25 0.1893 
 Tumor Ablation at 3-months-baseline 0.3161 -0.04731 0.6794  1.73 0.4367 
 Surgery at 3-months-baseline 0.6678 0.1520 1.1837  2.57 0.0944 
 Delta Delta 3-months-baseline -0.3517 -0.9827 0.2792 -1.11 0.5676 























Figure 4 Overall Quality of Life Experience between the two treatments. 
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Summary and Transition 
This chapter presented characteristics of the study population and hypotheses-
testing results using GEE. Patients enrolled in a randomized clinical trial for lung cancer 
were asked to volunteer in this comparative survey to test the effect of two treatments on 
HRQL at 1- and 3-months. Seventy volunteers (35 in each treatment) met the inclusion 
criteria and completed the surveys at the three points in time. Although randomization 
ensures equal groups at baseline, the 70 participants were self-selected and not 
randomized. There were significant differences between the two treatment groups in 
physical symptoms and average symptomatic distress but not overall quality of life 
experience.  
Testing of the GEE assumptions indicated that the assumptions were met. The 
research questions investigated the association for physical functioning, symptomatic 
distress, symptom burden, and overall quality of life experience of HRQL dimensions 
between two treatments and at three different time points. The null hypothesis was not 
rejected for physical functioning, symptomatic distress, and overall quality of life 
experience; there were no significant differences in the effect of surgery and tumor 
ablation treatment on all three HRQL domains at 1-month and at 3-months.  
In this chapter, I presented findings for the research questions and hypotheses, 
characteristics of sample, and statistical analysis. Chapter 5 includes the interpretation of 
findings, limitations of the study, recommendations for future research, practice, 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to assess the effect of lung cancer treatment on 
HRQL domains. I assessed the impact of surgery or tumor ablation treatment on HRQL 
physical functioning, symptomatic distress, and the overall quality of life experience 
among older adults. In this chapter I present a summary of key findings and interpretation 
of findings, along with study limitations, recommendations for future studies, and 
implications for practice and social change.  
The incidence of most types of cancers is age-dependent and the number of older 
adults 65 years and above is expected to reach 88.5 million by 2050 (U.S. Census 
Bureau, 2010). Both life expectancy and lung cancer survival are expected to increase 
due to better diagnostic technology, different treatment modalities, and disease 
prevention and control. I designed my study with three research questions to assess the 
effect of treatment modality on HRQL among older adults with small-cell lung cancer. 
The design of the study was an ancillary comparative survey among older adults 
undergoing treatment with either surgery or tumor ablation as part of a randomized 
clinical trial of lung cancer. Seventy patients completed an HRQL analog assessment 
with repeated measures of physical functioning, symptomatic distress, and overall quality 
of life experience.  
Summary of Findings 
Patients who were newly diagnosed and already enrolled in a randomized clinical 
trial of lung cancer treatment were recruited to participate in a comparative survey 




HRQL domains, physical functioning, symptomatic distress, and overall quality of life 
for the lung experience were assessed using analog scales to measure the effect of the 
treatment on HRQL. Seventy volunteers (35 in each treatment) met the inclusion criteria 
and completed all the surveys. Although randomization ensures equal groups at baseline, 
the 70 participants for the comparative survey were self-selected and not randomized. At 
baseline there were significant differences between the two treatment groups in average 
symptomatic distress (p = .0070) but not physical functioning (p = .0240; Bonferroni 
adjusted p < .016), or overall quality of life experience scores (p = .1893).  
The demographic characteristics by treatment modality at baseline were only 
significantly different in age (p = .0049) with mean age 66 for tumor ablation and 65 
years for surgery patients. Two-thirds (65.8%) of surgery patients were female, over half 
(55.3%) were married, and over two-thirds (68.4%) earned less than $75,000 annually. 
Two-thirds (65.4%) of tumor ablation patients had high school or less education, one-
third (34.6%) were widowed and over a fourth (27.3%) refused to provide their income.  
The three research questions I proposed were analyzed using GEE to test whether 
there were differences in the effect of two treatment modalities and repeated measures on 
HRQL among older adult lung cancer patients already participating in a randomized 
clinical trial. Each research question focused on a different HRQL domain, including 
self-reported horizontal visual analog measures of physical functioning, symptomatic 
distress, and overall quality of life for the lung cancer experience. Since repeated 
measures introduce an inflated risk of Type I error, a Bonferroni correction to adjust the 
p-value was required. The calculated criteria to reject the null thus was p < .016 instead 




treatment domain were graphed for visual comparison between the two treatments over 
time.  
The first research question examined the effect of surgery and tumor ablation 
treatments on physical functioning during the first three months after treatment. GEE 
analysis indicated that there were no significant differences in treatment effect on 
physical functioning between patients treated with surgery and tumor ablation at both 
follow-up times. However, the graph of computed means indicated that physical 
functioning was higher for tumor ablation compared to surgery at 3-months after 
treatment, while surgery was almost the same as the mean of tumor ablation at 1-month 
post-treatment. The null hypothesis was not rejected.  
The second research question examined the effect of surgery and tumor ablation 
treatment on symptomatic distress during the first three months after treatment. GEE 
analysis indicated that there were no significant differences in treatment effect on 
symptomatic distress between patients treated with surgery and tumor ablation at both 
follow-up times. However, the graph of computed means indicated that symptomatic 
distress was higher for tumor ablation compared to surgery at 3-months after treatment, 
while the mean symptom burden for surgery was slightly higher than the mean of tumor 
ablation at 1-month. The null hypothesis was not rejected.  
The third research question examined the effect of surgery and tumor ablation 
treatment on overall quality of life lung experience during the first 3 months after 
treatment. GEE analysis indicated that there were no significant differences in treatment 
effect on overall quality of life experience between patients treated with surgery and 




that overall quality of life experience was higher for tumor ablation compared to surgery 
at 3-months, while surgery was almost the same as the mean of tumor ablation only at 1-
month. The null hypothesis was not rejected.  
Interpretation of Findings 
The findings from the present study are consistent with prior literature in that 
none of the studies whether using EORTC, FACT-L, or LCSS document significant 
differences among the treatment modalities. A comparison of studies that examined 
physical and quality of life domains using all the scales developed to date were presented 
in Chapter 1 (Tables 1 and 2). A synthesis of the quality of life domains by treatment 
modality revealed that assessment of tumor ablation on HRQL has received minimal 
attention. In this study, I sought to fill this gap by assessing the effect of treatment with 
tumor ablation and surgery on HRQL domains of physical functioning, symptomatic 
distress, burden index, as well as overall quality of life of the lung cancer experience. 
Although no further interpretation can be made on the hypotheses-testing findings, the 
independent prognostic value of HRQL domains on survival merits interpretation and 
discussion (Yun et al., 2016).  
Physical functioning. Physical functioning consists of six symptoms: pain, 
dyspnea, appetite, fatigue, cough, and hemoptysis. Findings from the comparative survey 
indicated that some symptoms developed or increased with time progression (1-month 
through 3-months after treatment). The four most prevalent symptoms were pain, 
appetite, fatigue, and dyspnea. The development of these four symptoms implies that 
older lung cancer patients who go through surgery or tumor ablation may develop all or 




four most prevalent symptoms in this study drove the physical functioning and lung 
cancer experience.  
According to Yun et al. (2016) scores for poor indicators of survival after surgical 
treatment suggest that physical functioning (dyspnea, anorexia, diarrhea, cough, personal 
strength, anxiety, and depression) were associated with poor survival. The adjusted Cox 
proportional hazard ratio, for example, for overall physical functioning was 2.39 while 
for dyspnea was 1.56; the authors concluded that these predictor symptoms retained their 
independent prognostic power of survival. Family members, spouses, and care givers 
need to be educated about the possible development of these major lung cancer 
symptoms that affect physical functioning in order to prepare and educate patients when 
the need arises.  
However, Poghosyan, Sheldon, Leveille and Cooley (2013) found that a different 
set of symptoms drive the physical functioning and lung cancer experience. At 1 month 
after surgery, the most prevalent symptoms were pain, fatigue, dyspnea, and coughing 
(Poghosyana et al. 2013). Pain and dyspnea scores remained significantly worse 
compared to baseline when measured 3-4 months after surgery in five of the eight studies 
reviewed by Poghosyana et al. However, the significance of these symptoms varied by 
the type of surgery and patient’s age. Yang et al. (2012) also reported that almost all 
symptom scales indicated a 10% or greater reduction and clinically important decline 
including pain, fatigue, cough, dyspnea, and appetite. Wildstein, Faustini, Henschke, and 
Ostroff (2011) found that dyspnea and distressed mood were associated HRQL 
impairments. Since a majority of those who develop lung cancer are smokers or exposed 




symptom control, and physical function, are needed to enhance HRQL after lung cancer 
treatment.  
Symptomatic Distress. Hollen et al. (1999) and Yang et al. (2012) reported lack of 
differences in symptomatic distress across repeated measures using the LCSS. However, 
Yang et al. (2012) reported that among patients whose quality of life declined, 
significantly worsened symptoms were fatigue, pain, dyspnea, and appetite. Symptom 
burden did not lessen among participants who reported improvement, suggesting 
survivors might have adapted to their physical condition (Yang et al., 2012). The study 
by Hollen et al. (1999) measured symptomatic distress on patients treated with 
chemotherapy. The results indicated that fatigue, appetite, dyspnea, and pain contributed 
the greatest variance toward symptomatic distress. Other studies reported similar 
outcomes where all the same four predictors contributed the greatest variance toward 
symptomatic distress (Hollen et al., 1999; 2004; Wildstein, et al., 2011; Yang et al., 
2012).  
Overall Quality of Life Experience for Lung Cancer. Findings from the present 
study found no significant differences in overall quality of life for patients who had 
surgery or tumor ablation. Because HRQL outcomes research in lung cancer focuses 
mainly on short-term survival and quality of life, findings are not conclusive and require 
longer periods of observation (Yang et al., 2012). Some studies report overall quality of 
life for the lung cancer experience significantly lower at repeated measures but a 
clinically important decline and improvement in overall quality of life. Yang et al. (2012) 
found a clinically important decline and improvement in overall quality of life, where the 




decreased to 75 at 4 years. A score of 80 is equivalent to healthy populations. Lower 
quality of life warrants a design that provides frequent quality of life assessment 
throughout a clinical trial and use of instruments that focus on the primary issues of 
concern (Hollen et al., 1999; 2004; Wildstein, et al., 2011; Yang et al., 2012). The 
findings from this study suggest that the use of HRQL questionnaires during the first 
three months after surgery and tumor ablation may provide prognostic information but 
further studies are needed to evaluate the potential clinical value of these instruments. 
Recommendations include a demand for targeted interventions to improved HRQL. 
Theoretical Application 
The framework that guided this study was the lung cancer quality of life model. I 
used only three of the model’s quality of life dimensions to conceptualize my study: the 
physical, functional, and overall quality of life dimension (Figure 1). The physical 
dimension is the basic dimension that influences functioning as well as overall experience 
of quality of life among those with lung cancer. The developer of this model 
conceptualized the dimension of function as distinct from the physical dimension, where 
physical dimension is related to activities of daily living (walking, eating, bathing), and 
function reflects cognitive and social functioning. During the initial stages of lung cancer, 
the level of function may not be evident, and that the disease is affecting cognitive and 
social functioning (Hollen et al., 1995). HRQL represents a separate dimension and 
serves as the measure of the outcome or the effect of lung cancer on the physical and 
functional dimensions.  
The findings from this comparative survey study confirm the application of the 




three domains studied, the mean HRQL scores were higher for tumor ablation compared 
to surgery at 3 months across the three domains, and about the same for physical 
functioning and overall quality of life for the lung cancer experience at 1-month follow-
up. However, the mean HRQL for symptomatic distress at 1 month was higher for 
surgery compared to tumor ablation. This reversal favoring the less invasive treatment 
suggests that symptomatic distress is associated with severity of treatment, which in the 
case of surgery makes sense. In the case of lung cancer treatment burden symptoms 
parallel disease symptoms. HRQL is a multidimensional concept that interprets a 
patient’s health status because proliferation of disease-related symptoms and treatment-
induced toxicity are inversely related to HRQL (Bottomley et al., 2003; Echteld et al., 
2007; Pallis et al., 2010).  
Strengths and Limitations of the Study 
 The findings of this study have significance for several reasons. First, the analysis 
supports current practice patterns where there is no reported effect of treatments on 
HRQL physical functioning, symptomatic distress, and overall quality of life for the lung 
cancer experience. Second, although the sample size was 35 for each treatment and 
considered a small sample, it had at least 80% power to detect differences. Another 
strength of the study was the fact that to be eligible for the randomized clinical trial, 
participants in the comparative survey underwent pathological staging which is more 
objective than clinician-base and allows precise exclusion of stage IV lung cancer 
patients. Most studies rely on clinically staged lung cancer.  
There were limitations to the generalizability, validity, and reliability, either 




study was designed to minimize, or actions taken during the study. The use of a small 
sample from one hospital and geographic area may limit the generalizability of the 
findings. Most studies in cancer treatment and HRQL are either underpowered or fail to 
report any power calculations (Echteld et al., 2007; Melin-Johansson et al., 2010). 
Sample size calculations for the present study indicated that 30 patients in each treatment 
group would yield an 80% power to detect differences at the p < .05 significance level.  
Despite a 12.5% (10/80) attrition rate after consenting to participate in the 
ancillary study, the resulting sample with complete baseline and follow-up data was 
above the calculated sample size (n=35 for each group). Movsas et al. (2016) conducted a 
secondary analysis of pooled data from 185 institutions in the U.S. and Canada enrolling 
patients with lung cancer stage III in randomized clinical trials. Movsas et al. (2016) 
wanted to test the effect of high-dose radiation compared to standard dose on HRQL. All 
the sites were part of the Radiation Therapy Oncology Group which uses the FACT-Lung 
Cancer Subscale to measure HRQL. Movsas et al. (2016) reported a 30% attrition rate 
from baseline to 3-months. The attrition rate of the present study (12.5%) was much 
lower than published studies (Movsas et al., 2016) and especially stage IV lung cancer 
(average attrition rates 29.1 and 46.6%) where palliative care is the intervention 
(Kassianos, Loannou, Koutsantoni & Charalambous, 2018).  
Recommendations for Research 
The recommendations for further research are grounded in the strengths and 
limitations of the current study, as well as the literature reviewed in chapter 2. Comparing 
the effectiveness of tumor ablation and surgery is difficult. Randomized trials either have 




One suggestion is the need to determine whether the LCSS instrument would work for all 
age groups who may be diagnosed with lung cancer. Another school of thought is that 
this study may help health care providers, public health professionals, oncologists and 
other professionals in the field of cancer research to make informed decisions on lung 
cancer for older adults.  
While different instruments have been used to examine HRQL to guide 
physicians and health care providers in their decision-making to select a cancer treatment, 
such instruments have measured a range of conditions, but the LCSS in this study was 
developed specifically to measure the effect of treatment for lung cancer. The ease with 
which participants find the LCSS survey analogue questions and the short time span to 
answer the questions could make the LCSS the instrument of choice for HRQL studies. 
There are numerous studies assessing the effect of chemotherapy on lung cancer HRQL 
as chemotherapy is the treatment of choice for early stage lung cancer as well as 
nonresectable cancers for which surgery is not an option (Kassianos et al. 2018).  
The data gathered from this study using 70 older adult lung cancer patients can be 
used to extrapolate for interpretation of scores of the LCSS in larger populations. The 
results and findings from this study might also be interesting to use to bridge the gap in 
the literature especially in the field of tumor ablation where quality of life is not 
adequately investigated. Physicians face barriers to make consistent decisions during 
treatment, such as cost control, professional judgment, as well as demands to include 
patients in decision-making (Parker, Ritchie, Kirchner, & Owen, 2009, p. 972-973).  
There should be a study using this instrument as a pretest and posttest after an 




existing educational treatment and management guidelines could be of help to 
oncologists, and healthcare providers to gain more insight into management and 
treatment of lung cancer especially in the older adult. Finally, for researchers looking to 
design studies with endpoints of mortality and morbidity, the findings from this study 
suggest stratifications of patients by life expectancy and examination of complications 
and mortality for at least 2 years after treatment.  
Recommendations for Practice 
HRQL research is an important aspect of cancer clinical trials and a major 
concern for cancer patients and their families. Findings from HRQL research are key to 
the provision of evidence that addresses how much additional time a patient can gain with 
a particular treatment and how valuable that time can be made. Thus, HRQL impacts both 
future research and treatment decisions for clinicians (Bottomley et al., 2003; Yun et al., 
2016). HRQL is a multidimensional concept that interprets a patient’s health status 
because increases in disease-related symptoms and treatment-induced toxicity are 
inversely related to HRQL (Bottomley et al., 2003; Echteld et al., 2007; Pallis et al., 
2010; Yun et al., 2016). 
Evidence-based clinical recommendations are difficult to reach because evidence 
on adults 65 years of age and older is dismal. Despite the high incidence of lung cancer in 
older adults, they are underrepresented in clinical trials (Sacher, Le, Leighl, & Coate, 
2013). Providers and patients lack certainty as to the optimal treatment for lung cancer. 
Recommendations for practice include increasing knowledge and awareness of the 
importance of educating high-risk individuals about lung cancer. The results of this study 




more importantly tumor ablation where there is scant amount of knowledge in the field. 
For the clinician counseling patients, this study provides further incentive for frank 
discussion and individualized decision-making, considering a patient’s life expectancy, 
desire for a long-term cure, and appetite for treatment-related complications 
Implications for Social Change 
The study may influence positive social change by providing information that 
may improve both survival and HRQL of older lung cancer patients, reducing self-care, 
healthcare cost, and complement existing information available to patients, family, and 
providers. Most older lung cancer patients have complex medical histories as well as a 
myriad of comorbidities. Older lung cancer patients present unique characteristics such as 
physiological changes in organ function and pharmacokinetics, that make the choice of 
the best treatment more difficult and therefore are often undertreated (Di Maio & 
Perrone, 2003).  
Lung cancer is often not diagnosed until late in progress when disease-mortality is 
increased. Because of the aggressive process of late stage cancer, the frailty of older 
adults, and the impact on physiological and psychological effect that lung cancer 
treatment has on older adult assessment of physical functioning, symptomatic distress and 
lung cancer experience as HRQL is of major importance. Lung cancer treatment 
improves both survival and quality of life, yet treatment is underutilized among older 
adults.  
Hence, the results of this study may help healthcare providers and older lung 
cancer patients to decide the mode of lung cancer treatment to adopt based on symptoms. 




educational programs related to the diagnosis and treatment of lung cancer or any other 
type of cancer to the older adult community. Findings from this study may also provide 
evidence-based guidelines on lung cancer to the lung cancer patients. 
Effective educational programs and guidelines may influence how oncologists 
and other healthcare providers, manage and perceive lung cancer. The potential impact 
for positive social change may be positioned at the provider, organizational, and policy 
levels. The results of this study may help providers, research and cancer centers to tap 
into the information which might aid their current treatment and standard of care to 
include evidence based medical practices. 
Conclusion 
The purpose of this study was to assess the effect of lung cancer treatment on 
HRQL domains. The study assessed the impact of surgery and tumor ablation treatment 
on HRQL physical functioning, symptomatic distress, and the overall quality of life for 
the lung cancer experience among older adults. The research design and approach of the 
study was an ancillary comparative survey among older adults undergoing treatment with 
either surgery or tumor ablation as part of a randomized clinical trial of lung cancer. 
Seventy patients completed an HRQL analog assessment with repeated measures of 
physical functioning, symptomatic distress, and overall quality of life experience.  
This ancillary comparative survey study examined three dimensions of HRQL 
among older adult lung cancer participants undergoing treatment with surgery and tumor 
ablation. The physical domain included individual pain, appetite, shortness of breath, 
fatigue, cough, and hemoptysis. In addition, the domains of symptomatic distress and 




HRQL at 1-month and 3-months did not indicate significant differences in the effect from 
treatment with surgery and tumor ablation on physical functioning symptoms, 
symptomatic distress, average symptom burden index, and overall quality of life 
experience. The lack of significant differences in HRQL domains between the two 
treatments implies that either treatment is adequate for older adults with non-small cell 
lung cancer. Because participant attrition biases the findings towards the “healthy-effect” 
with participants with better well-being, more studies are needed to improve treatment 
decisions for more frail lung cancer patients and those with higher co-morbidity. 
Lung cancer incidence is increasing with the increasing aging of the U.S. 
population. In addition, the number of women with lung cancer has increased 
dramatically in the last decades and represent almost half of patients with lung cancer 
(Howlader et al., 2017). Lung cancer is the leading cause of death among all cancers. 
Despite a high incidence and median age of 70 years, uncertainty about the optimal 
treatment remains due to the systematic under-representations of older adults in clinical 
trials, and evidence exists that elderly patients are specifically excluded in the trial 
designs (Howlader et al., 2017; Pallis, et al., 2010); Sacher, Le, Leighl, & Coate, 2013).  
Both life expectancy and lung cancer survival are expected to increase due to 
better diagnostic technology, different treatment modalities, and disease prevention and 
control. Although the prognosis of lung cancer is poor, the quality of life is at least as 
important as the quantity of remaining life. HRQL is a useful concept which might be 
considered intangible to define; however, there are several important contributing factors. 
Culture, religion, prior experience, and the individual’s point of view may contribute to 




community. The measurement of quality of life in cancer clinical trials should 
concentrate on a few important categories such as physical symptoms, psychosocial 
factors, and should be simple rather than comprehensive.  
The representation of age and gender in the present study contributes to the 
literature in increasing evidence to better define the effect of treatment on HRQL and 
reduce uncertainty for selection of optimal treatment for older adults. The review by 
Sacher et al. (2013) of the 100 most cited trials of NSCLC, revealed that 33% of elderly 
were excluded and the average patient median age was 60.9 years. The mean age of the 
comparative survey sample was 66 and 65 for the two treatment groups, and two-thirds 
were women. However, according to the EORTC Elderly Task Force, Lung Cancer 
Group (Pallis, et al., 2014), treatment decisions should not be based just on chronological 
age but on functional age (Pallis, et al., 2010; Pallis, et al., 2014). Functional age includes 
evaluation of health, functional status, nutrition, cognition, and the psychosocial and 
economic context (Pallis, et al., 2010). The EORTC also recommends inclusion of 
patient’s life expectancy, preferences, functional age, comorbidities, and estimated 
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Appendix A: Demographic and Health Data 
Participant #_____ 
Interviewer_____ 
Protocol: Surgery: [___]     Tumor Ablation: [___] 
 
Your answers will help to facilitate a health-related quality of life study on 
surgery and tumor ablation. All of the information you give me will be strictly 
confidential, and when I report my results I will do it by groups and not by individuals. 
Do you have any questions before we start? 
 
1. What is your date of birth?  ______________ 
 
2. What is your gender? (Check one)  M [__]  F [__] 
 
3. What is the highest grade you completed in school? 
a. Not a High School graduate or equivalent [   ] 
b. High School graduate or equivalent  [   ] 
c. Some college     [   ] 
d. College graduate    [   ] 
e. Post-graduate or professional school  [   ] 
 
4. What race do you consider yourself? 
a. White      [   ] 
b. African-American or Black   [   ] 
c. Asian      [   ] 
d. American Indian or Alaskan Native  [   ] 
f. Native Hawaiian or other Pacific Islander [   ] 
g. Hispanic or Latino    [   ]  
h. Prefer not to answer     [   ] 
 
5. What is your marital status? 
 a. Single     [   ] 
 b. Significant Other   [   ] 
 c. Married     [   ] 
 d. Separated    [   ] 
 e. Divorced    [   ] 






Participant#[___] [___] [___] 
Interviewer: [___] [___][___] 
 
 
Now I would like to ask you some questions about your health. I am interested in 
knowing if you have gone through any of the following two treatment options or any 
other lung cancer therapy not mentioned below.  
 
6. Has your lung cancer been treated with any other therapy other than surgery, or 
tumor ablation? 
   
 [   ] No  
 [   ] Yes→ If yes, what type of therapy did you receive? 
   a. ___________________________ 
   b. ___________________________ 
   c. ___________________________ 
   d. ___________________________ 
 
7. What was your household income for the [ENTER LAST CALENDARYEAR]?  
 
[   ] $75, 000 and over or 








Appendix B: Questionnaire Permission Letter 
 
You have our permission to use the data 
 
kind regard,  
brambalduyck 
Hooiendonkstraat 4, 2801 Heffen 
tel: (0032) 479858733 




> From: fesdok@juno.com 
> Date: Mon, 29 Sep 2008 16:27:27 +0000 
>To: bram_sam@hotmail.com 
> Subject: Re: Standard Deviations 
Sir, 
Thank you very much for the response. I am looking forward for it. Sir, one more thing. 
Do I have your permission to use your data as stated in my first e-mail? I really 
appreciate your help.  
> 





Appendix C: Lung Cancer Symptom Scale (LCSS) 
 
Fee Waiver Agreement Form 
The Lung Cancer Symptom Scale (LCSS), a site-specific quality of life instrument, 
provides a practical measure for the lung cancer population.  The scale developers, 
Quality of Life Research Associates, LLC, having a business address at 3445 Seminole 
Trail, Suite 214, Charlottesville, VA, 22911, and the other entity) [see below] agree to 
the following conditions: 
 
 User’s Name (Typed):  FESTUS F. DOKYI  
 
 Organization:    WALDEN UNIVERSITY             
 






 Telephone #:    401-228-7754 (H)/401-954-8167 (C)  
 
      Fax #:    401-228-7754  
 
      E-mail:  FESDOK@JUNO.COM 
  
 
Name of Study (Typed):   QUALITY OF LIFE ASSESSMENT OF LUNG CANCER 
TREATMENT IN THE ELDERLY 
 
   
 
 Sponsor: NONE 
      (If none, so state) 
  
 
 Special Circumstances (e.g., Student Status, Non-Sponsored Study):   
STUDENT STATUS 
    
   
   
Terms of Agreement: 
 
1. User sends an abstract of the proposed study at the time of sending the agreement 
form. 
 
2. User agrees to use the LCSS for her/his own work, without distribution to other 
colleagues other than those involved in the trial, unless written approval is 





3. User agrees to use the LCSS for one trial only (as specified above).  For additional 
trials, new agreements will be needed.  
 
       4.     User agrees to cite all primary references for this measure by the LCSS 
developers.  
 




______Festus F. Dokyi________________________6/8/10________________ 
Signature of Applicant     Date 
 
_______________________________________________________ 






Appendix D: Scoring The LCSS 
Scoring Instructions Located at LCSS Website 
The LCSS is designed as a site-specific measure of quality of life (QL), particularly for 
use in clinical trials. It evaluates six major symptoms associated with lung malignancies 
and their effect on overall symptomatic distress, functional activities, and global QL. The 
philosophy behind the development of the LCSS is to provide a practical QL measure 
that reduces patient and staff burden in serial measurement of QL during the course of the 
trial. It captures in detail those dimensions most likely to be influenced by therapeutic 
interventions and evaluates other dimensions globally. It consists of two scales: one 
completed by the patient and an optional one for health care professionals ("counterpart 
observer") to provide context. 
Number of QL Dimensions/Domains: 
Five, with physical and functional in detail, and others captured globally. 
Scaling of items:  
Patient scale: 9 visual analogue scales (100 mm horizontal line). Patient puts a mark on 
line to indicate intensity of response to the items in question (0 = lowest rating; 100 = 
highest rating). Observer scale: 5-point categorical scale (100 = none; 75 = mild; 50 = 
moderate; 25 = marked; 0 = severe).  
Scoring:  
Patient scale: Scores equal length of line marked by patient. An average of the aggregate 
score of all 9 items is used for a total score. In addition, a subscore using the mean of all 
6 major symptoms ("average symptom burden index"), the single QL item, and/or 
individual items to report specific areas of change can be used. Observer scale: Score 
equals point value chosen by observer for each item. Aggregate score is used as well as 













Actual example will include a mark across one end of the range and this will be explained 





Lung Cancer Symptom Scale Symptoms and Patient Scoring Ranges 
 
Directions: 
Please place a mark along the line where it would best describe the symptoms of your lung cancer 
DURING THE PAST DAY (within the last 24 hours)—The questions here represent the actual Cards on 









  0 100 




How good is your appetite? 
 
 
As good as it could be 
 
As bad as it could be 
2. How much fatigue do you have? 
 
None As much as it could be 
3. How much coughing do you have? 
 
None As much as it could be 
4. How much shortness of breath do you have? 
 
None As much as it could be 
5. How much blood do you see in your sputum? 
 
None As much as it could be 
6. How much pain do you have? 
 
None As much as it could be 
7. How bad are your symptoms? 
 
I have none As bad as they could be 
8. How much has your illness affected your ability 
to carry on normal activities? 
 
Not at all So much that I can do 
nothing for myself? 
9. How would you rate the quality of your life 
today? 
Very high Very low 
 
 
 
